Preparative regimen for engraftment, growth and differentiation of non-hematopoeitic cells in vivo after transplantation

ABSTRACT

Disclosed are methods of obtaining an expanded population of mammalian ex vivo cells for treating a mammalian subject by (a) administering to a subject an effective amount of an agent that confers a growth disadvantage to at least a subset of endogenous cells at the site of engraftment; (b) administering to the subject an effective amount of a mitogenic stimulus for the ex vivo cells; and (c) administering the ex vivo cells to the subject, wherein the ex vivo cells engraft at the site and proliferate to a greater extent than the subset of endogenous cells, to repopulate at least a portion of the engraftment site with the ex vivo cells. The repopulated cells can be harvested or left at the engraftment site. Methods of treating brain injury in a subject by engrafting ex vivo cells at the site of injury are also described.

CROSS-REFERENCES TO RELATED APPLICATIONS

The present application is a continuation of, and claims the benefit andpriority to application Ser. No. 13/625,649, filed Sep. 24, 2012,entitled “PREPARATIVE REGIMEN FOR ENGRAFTMENT, GROWTH ANDDIFFERENTIATION OF NON-HEMATOPOEITIC CELLS IN VIVO AFTERTRANSPLANTATION,” which claims the benefit and priority to applicationSer. No. 12/032,615, filed Feb. 15, 2008 (now abandoned), and whichclaims the benefit and priority under 35 U.S.C. §119(e) to U.S.Provisional Application No. 60/890,444, filed Feb. 16, 2007, the entirecontents of each are hereby incorporated by reference for all purposes.

FIELD OF THE INVENTION

This invention relates to methods of cell transplantation therapy inwhich the subject is administered an effective amount of an agent thatconfers a growth disadvantage to at least a subset of endogenous cellsat the site of engraftment.

BACKGROUND OF THE INVENTION

Orthotopic whole organ transplantation is expensive and invasive.Moreover, there is an acute shortage of donor organs. Accordingly, celltransplantation has been considered as a potential alternative to wholeorgan transplantation. Cell transplantation has been around for twodecades but has not been clinically very useful because even whenprimary or stem cells can engraft in organs they often cannotselectively proliferate or repopulate the intended organ. Accordingly,cell transplantation without a preparative regimen of is ineffectivebecause of poor engraftment of the transplanted cells in the host organ.Administration of growth factors alone cannot offer selectiveproliferative/growth advantage to the transplanted cells over theresidual host cells and have not been used clinically.

There is a great clinical need for cell transplantation treatments whichcan restore an organ to health and provide for its biological functions.For instance, with respect to liver disease, more than 40,000 patientsdie of terminal liver diseases every year in the United States alone,and it is estimated that approximately 20 million suffer from liverdiseases (Hagmann, M., Science, 287:1185, 1187 (2000)). For those withinherited metabolic liver diseases or terminal liver failure, orthotopicliver transplantation (OLT) is the only treatment option, but most diewithout OLT because of a critical shortage of donor livers. Out of 1.3million patients who may benefit from OLT, only about 4000 patientsreceive it each year (Hagmann, M., Science, 287:1185, 1187 (2000)). Intheory, many patients with primary or metastatic cancers in the livercould also be cured, or have their survival and/or the quality of lifeimproved, by total hepatectomy with OLT. In practice, however, cancerpatients are rarely considered for OLT because of the long waiting listsfor donor liver.

In a clinical trial of hepatocyte transplantation (HT), 7.5 billionnormal allogeneic hepatocytes (representing ˜5% of the hepatocyte mass)were transplanted in a 10-year old girl with Crigler-Najjar syndrometype 1 (Fox, I. et al., N Engl J Med, 338:1422-1426 (1998)). Althoughthe study demonstrated the long-term safety of HT, only partialcorrection of the metabolic disorder was achieved, because of the lackof proliferation of the engrafted donor hepatocytes. Similarly, aclinical trial of ex vivo hepatic gene therapy in patients with familialhypercholesterolemia failed to demonstrate convincing therapeutic effect(Raper, S. et al., Ann Surg, 223:116-126 (1996); Grossman, M. et al.,Nat Med, 1:1148-1154 (1995)) because only a fraction of the transplantedcells engrafted and those that engrafted failed to proliferate in thehost liver.

While it has been established that HT can be employed safely in humans,its applicability remains limited by:

-   -   (i) a critical shortage of donor hepatocytes,    -   (ii) the number of hepatocytes that can be transplanted safely,        without causing portal hypertension,    -   (iii) the inability of the transplanted hepatocytes to        proliferate in the host liver, and    -   (iv) lack of a noninvasive method to evaluate the repopulation        of transplanted hepatocytes in the liver.

New strategies to provide a selective growth advantage to the engraftedcells over the host endogenous cells of the target organ are needed.These strategies can allow the diseased host cells to be replacedprogressively with normal ones.

BRIEF SUMMARY OF THE INVENTION

In a first aspect, the invention provides a method of treating amammalian subject with an organ or tissue having a reduced function byengrafting mammalian ex vivo cells which supplement the function of theorgan or tissue and by promoting proliferation of the engrafted cells atthe site of engraftment by (a) administering to the subject an effectiveamount of an agent that confers a growth disadvantage to at least asubset of endogenous cells at the site of engraftment, (b) administeringto the subject an effective amount of a mitogenic stimulus or stimulifor the ex vivo cells, and (c) administering the ex vivo cells to thesubject, wherein the ex vivo cells engraft at the site and proliferateto a greater extent than the subset of endogenous cells, therebyrepopulating at least a portion of the engraftment site with the ex vivocells, so that the repopulated ex vivo cells supplement the function. Insome embodiments, the organ with the reduced function is intestine,brain, liver, lung, kidney, pancreas, eye, testes, ovary, or skin. Inother embodiments, the organ or tissue with the reduced function wasdamaged by irradiation, trauma, chemical or drug exposure, a geneticillness, or an infectious disease. In additional embodiments, the exvivo cells can be adult somatic cells, adult progenitor cells, adultstem cells, embryonic progenitor cells, fetal cells, and embryonic stemcells from the same species as the subject or from a different mammalianspecies than the subject. The ex vivo cells can be autologous orheterologous with respect to the subject. In yet other embodiments, theex vivo cells are cultured prior to their administration to the subject.In still other embodiments, the ex vivo cells are harvested and sortedfrom a heterogeneous cell population prior to their administration tothe subject. In some embodiments, the engrafted cells are of the samecell type as the cells of the organ or tissue at the site ofengraftment.

In other embodiments, the agent that confers a growth disadvantage to atleast a subset of endogenous cells is radiation (e.g. x-ray and gammaray), a cytotoxic chemical, ultrasound, heat, biological agent,degenerative proteins, and proteins or nucleic acids that suppress celldivision. The protein may be an antibody directed to a cell surfacereceptor that regulates cell division or apoptosis.

In other embodiments, the mitogenic stimulus may comprise one or moregrowth factors for the cell type to be engrafted. In some embodiments,the growth factors are one, two, three or more growth factors selectedfrom the group consisting of HGF, EGF, FGF, VEGF, NGF, Il-6, TNF-alpha,CTNF, R-spondin 1, Noggin, and TWEAK. In other embodiments, theadministered ex vivo cells comprise, contain, or include a heterologousgene that increases their intrinsic proliferation capacity or survival.In some embodiments, the mitogenic stimulus can comprise a biologicalagent, antibody or peptide factor that increases the proliferationcapacity of the donor cells or comprise a procedure that deliberatelyinjures the engraftment site to enable entry and integration of thetransplanted cells into the host parenchyma and/or to provide acompensatory growth signal for the ex vivo cells. In some furtherembodiments, the procedure is a surgical resection, portal vein branchligation, portal vein embolism by chemotherapeutic agents or toxins,radiofrequency ablation, radiosurgical ablation, or high frequencyultrasonic ablation of the a portion of the donor organ.

The subject to be treated is a mammal, preferably, a human. The ex vivocells can be heterologous to the engraftment site. In some otherembodiments, the engraftment site is the organ or tissue having thereduced function or elsewhere. In some embodiments, the ex vivo cellsexpress a heterologous nucleic acid for gene therapy of the reducedfunction. In further embodiments of any of the above, immunosuppressivetherapy is also administered to the host following administration of theex vivo cells.

There is, in some further embodiments, a proviso that the organ ortissue is not bone marrow or a proviso that the damage is not due tocancer or a cancer. There is, in some further embodiments, a provisothat the damage to be treated is one which was not caused by exposure tothe agent to be used to confer the growth disadvantage. There is, insome further embodiments, a proviso that the damaged organ or tissue isnot the pancreas or islet cell. In some embodiments, there is a provisothat the mammalian growth factor is not HGF or a nucleic acid encodingHGF (e.g., an adenoviral vector comprising a nucleic acid encoding HGF).

In some embodiments, the ex vivo cell is derived from a precursor cellwhich is capable of differentiating into a cell type of the engraftmentsite or of the organ or tissue with the reduced function. In someembodiments, the ex vivo cell can be an epithelial cell, a hepatocyte, anerve cell, a muscle cell, a kidney cell, a pancreatic islet β-cell or aprecursor thereto. In some embodiments, the ex vivo cells aregenetically modified to modulate or eliminate the expression of anendogenous gene or to express a gene encoding a protein not endogenousexpressed in the cell. In some embodiments, the cells have beengenetically modified to enhance their proliferation rate or survivalwithout immortalization. In some further embodiments, the cells aregenetically modified to become immortalized.

Where the ex vivo cells are sensitive to the growth disadvantagingproperties of the agent that confers a growth disadvantage to at least asubset of the endogenous cells of the organ, step (a) is performedbefore step (c). Otherwise steps (a), (b) and (c) may be performedconcurrently or in any order. With a preferred order having step (a)being performed first and then step (b) followed by step (c), or steps(b) and (c) being performed concurrently, or step (c) being performedbefore step (b). In instances, where the ex vivo cells are antigenicallydifferent from the host, immunosuppressive therapy may be furtheradministered.

In some embodiments, the ex vivo cell expresses a protein not expressedby the host tissue at its engraftment site and the presence of theprotein is used to selectively detect the ex vivo cells as opposed tothe host cells at the engraftment site. In a further embodiment, theprotein is an enzyme whose reaction products are detected using magneticresonance spectroscopic imaging. In some further embodiments still, theprotein is creatine kinase and a reaction product (e.g.,phosphocreatine) containing ³¹P is detected using magnetic resonancespectroscopic imaging in vivo.

In additional embodiments, the invention also provides a method oftreating a subject with a damaged organ or tissue/organ or tissue havinga reduced function by grafting ex vivo cells onto the organ or tissueand promoting proliferation of the engrafted cells by (a) administeringto the subject an effective amount of an agent that confers a growthdisadvantage to at least a subset of endogenous cells of the damagedorgan; (b) administering to the subject an effective amount of amitogenic stimulus for the ex vivo cells; and (c) administering the exvivo cells to the organ, wherein the ex vivo cells engraft andproliferate and the endogenous cells having a growth disadvantage failto proliferate or proliferate at a reduced rate or lesser rate than theengrafted ex vivo cells, thereby repopulating the damaged organ ortissue with ex vivo cells and treating the subject with the damagedorgan or tissue. Where the ex vivo cells are sensitive to the growthdisadvantaging properties of the agent that confers a growthdisadvantage to at least a subset of the endogenous cells of the organ,step (a) is performed before step (c). Otherwise steps (a), (b) and (c)may be performed concurrently or in any order. With a preferred orderhaving step (a) being performed first and then step (b) followed by step(c), or steps (b) and (c) being performed concurrently, or step (c)being performed before step (b). The damage can be due to trauma,surgery, or disease. The disease may be inherited/genetic or caused byan environmental agent (e.g., dietary deficiency, drug treatment,radiation, chemical exposure, or infectious agent). In some embodiments,the damaged organ is the liver, intestine, pancreas, heart, kidney, or apart of the central nervous system (e.g., brain, spinal cord). In otherembodiments, the damage to be treated is not cancer and/or a result of acancer. In yet other embodiments, the subject does not have cancer. Thesubject can be a mammal (e.g., human, a non-human primate (e.g., achimpanzee, baboon), a rodent (e.g., a mouse, a rat) a pig, a rabbit).In instances, where the ex vivo cells are antigenically different fromthe host, immunosuppressive therapy may be further administered. In someembodiments, the methods is practiced in utero to treat a congenitaldisease. Accordingly, in some embodiments the organ or tissue to beengrafted in utero is a fetal organ or tissue or the organ whosefunction is to be supplemented in utero is a fetal organ or tissue.

In some embodiments, the ex vivo cells are adult somatic cells, adultprogenitor cells, adult stem cells, embryonic progenitor cells, fetalcells, xenogenic cells, or embryonic stem cells. The ex vivo cells canbe fetal hepatocytes, amniotic epithelial cells, “oval” cells and“small” hepatocytes. In still other embodiments, the ex vivo cells areheterologous to the subject. In still other embodiments, the ex vivocells are autologous to the subject. In additional embodiments, the exvivo cells are the same cell type as an endogenous cell type of theorgan or tissue or heterologous to the organ or tissue. In otherembodiments, the ex vivo cells are not an endogenous cell type of theorgan or tissue. The ex vivo cells can be cultured prior toadministration. In some embodiments, the ex vivo cells express aheterologous nucleic acid for gene therapy. In some embodiments, thegrafted cells repopulate the damaged organ or tissue with healthy cellsof the same type and/or function as those whose growth was targeted tobe disadvantaged, or disadvantaged, by administration of the agent thatconfers a growth disadvantage. In some embodiments, the ex vivo cellsare bone marrow progenitor cells, embryonic stem cells, neuralprogenitor cells, endothelial progenitor cells, progenitor cellsobtained from peripheral blood, cord blood cells, amniotic epithelialcells, fetal cells, organ-specific stem cells, such as, oval cells,primary hepatocytes, primary parenchymal cells, human umbilicalmicrovascular endothelial cells, blood outgrowth endothelial cells,glia, or human brain microvascular endothelial cells.

The agent that confers a growth disadvantage to at least a subset ofendogenous cells of the damaged organ can be radiation (e.g., X-rays,gamma rays), cytotoxic chemicals (e.g., a compound which is hepatotoxicor toxic to liver parenchymal cells or more preferably selectively toxicfor such; ultrasound; heat (e.g., focused ultrasound induced heating);biological agents; degenerative proteins; or proteins that suppress celldivision. In some embodiments, the agent is partial liver irradiation(e.g., using 3-D conformal RT). For instance, hepatic irradiation can bedelivered to portions of the liver while other portions are shielded(e.g., the right anterior lobes of the liver can be irradiated aftershielding the left anterior and right posterior and caudate lobes usinglead shields). The radiation in some embodiments is StereotacticRadiosurgery (SRS), Intensity-Modulated Radiation Therapy (IMRT),dynamic adaptive radiation therapy, or image-guided radiation therapy(IGRT). Accordingly, in some embodiments, use of spatially confined,focally ablative regimen of single-fraction or hypofractionatedirradiation for stem cell engraftment and growth of human primaryparenchymal cells is contemplated.

The mitogenic composition can be a mammalian growth factor (e.g.,hepatocyte growth factor (HGF), TGF-beta (transforming growthfactor-beta), neurotrophins (NGF, BDNF, and NT3), Granulocyte-colonystimulating factor (G-CSF), Granulocyte-macrophage colony stimulatingfactor (GM-CSF), Platelet-derived growth factor (PDGF), Erythropoietin(EPO), Thrombopoietin (TPO), Myostatin (GDF-8), Growth Differentiationfactor-9 (GDF9), basic fibroblast growth factor (bFGF or FGF2),epidermal growth factor (EGF), fibroblast growth factor (FGF), vascularendothelial growth factor (VEGF), nerve growth factor (NGF),interleukin-6 (Il-6), tumor necrosis factor-alpha (TNF-alpha),circulating tumour necrosis factor (CTNF), R-spondin 1, Noggin, c-metactivating antibody, and tumor necrosis factor-like weak inducer ofapoptosis (TWEAK, growth receptor ligand) which can be selective for thetype of transplated cell. The mitogen can be administered in the form ofgene therapy or as a protein preparation. The protein may berecombinant. In some embodiments, the proliferative stimuli or mitogeniccomposition can be either a combination of growth factors such asHGF+tri-iodo-thyronine (T3), or HGF+EGF, or a combination of growthfactor and compensatory regenerative stimuli.

In some embodiments, the organ damage is a degenerative disease (e.g, aneurodegenerative disease). In other embodiments, the organ damage is adisease selected from the group consisting of liver cancer, hepatitis A,hepatitis B, hepatitis C, hepatic fibrosis, cirrhosis, Wilson's disease,alpha1-antitrypsin disease, Niemann-Pick disease, Tyrosinemia Type I,Protophophyria, Ornithine transcarbamylase deficiency, Parkinson'sdisease, Alzheimer's disease, and Crohn's disease; hepatitis,inflammation of the liver, caused mainly by various viruses but also bysome poisons and/or chemicals (e.g., carbon tetrachloride), autoimmunityor hereditary conditions; hemochromatosis; primary sclerosingcholangitis; primary biliary cirrhosis, autoimmune disease of small bileducts; Budd-Chiari syndrome, obstruction of the hepatic vein; andGilbert's syndrome, a genetic disorder of bilirubin metabolism; biliaryatresia, alpha-1 antitrypsin deficiency, alagille syndrome, andprogressive familial intrahepatic cholestasis. In some embodiments, theorgan with the reduced function is the kidney, liver, brain, heart, eye,testes, ovary, skin, lung, pancreas, spleen, or kidney. In someembodiments, the ex vivo cell is derived from a precursor cell which iscapable of differentiating into a cell type of the engraftment site ororgan with the reduced function. In some embodiments, the ex vivo cellcan be an epithelial cell, a hepatocytes, a nerve cell, a muscle cell, apancreatic islet β-cell or a precursor thereto.

Accordingly, the invention provides a method of treating a subjecthaving organ damage due to radiation exposure, infection, or toxicexposure, the method comprising the steps of administering to thesubject an effective amount of a mitogenic composition; andadministering ex vivo cells to the subject, wherein the ex vivo cellsengraft and proliferate, thereby repopulating the damaged organ. In someembodiments, the grafted cells can serve to repopulate the damaged organwith healthy cells of the same type and/or function as those damaged bythe radiation exposure, infection or toxic exposure. In someembodiments, the damaged organ is the liver, intestine, pancreas, heart,kidney, lungs, brain, spleen eye, testes, ovary, or spinal cord, or apart of the central nervous system (e.g., brain, spinal cord). In otherembodiments, the damage to be treated is not cancer and/or a result of acancer. In yet other embodiments, the subject does not have cancer. Thesubject can be a human, a non-human animal, a mammal (e.g., human, anon-human primate (e.g., a chimpanzee, baboon), a rodent (e.g., a mouse,a rat) a pig, a rabbit).

In some embodiments, the ex vivo cells are also adult somatic cells,adult progenitor cells, adult stem cells, embryonic progenitor cells, orembryonic stem cells. In still other embodiments, the ex vivo cells areheterologous to the subject. In still other embodiments, the ex vivocells are autologous to the subject. In additional embodiments, the exvivo cells are the same cell type as an endogenous cell type of theorgan or heterologous to the organ. In other embodiments, the ex vivocells are not an endogenous cell type of the organ. The ex vivo cellscan be cultured prior to administration. In some embodiments, the exvivo cells express a heterologous nucleic acid for gene therapy. Themitogenic composition in this aspect can be a mammalian growth factor(e.g., HGF, EGF, FGF, VEGF, NGF, Il-6, TNF-alpha, CTNF, R-spondin 1,Noggin, and TWEAK).

In some embodiments, the invention provides methods of treating an organdamaged by exposure to toxic chemicals. The toxic effects and targetorgans for a variety of chemicals are disclosed in Registry of ToxicEffects of Chemical Substances (RTECS), RTECS (NIOSH 1980 or latereditions, including 1995). RTECS is a database of toxicity informationcompiled from the published scientific literature. Prior to 2001, RTECSwas maintained by US National Institute for Occupational Safety andHealth (NIOSH). Now it is maintained by Elsevier MDL. See, also, Olsonet al. Ed., Poisoning and Drug Overdose, 5th Edition, published byMcGraw Hill/Lange for a listing of toxic agents and their effects andtarget organs.

There is in some further embodiments, a proviso that the organ is notbone marrow or a proviso that the damage is not due to cancer or cancer.

In one embodiment, endothelial (progenitor, microvascular and/ordifferentiated) cell transplantation is used to rescue radiation-inducedgastro-intestinal injury, especially after exposure to irradiation tothe intestines or whole body.

In another embodiment, the invention provides a method of grafting exvivo cells onto a liver or other organ and promoting proliferation ofthe engrafted cells in a subject by (a) administering to the subject aneffective amount of an agent that confers growth disadvantage to atleast a subset of endogenous cells of the liver or other organ; (b)administering to the subject an effective amount of a mitogeniccomposition; and (c) administering the ex vivo cells to the subject,wherein the ex vivo cells engraft and proliferate and the endogenouscells having a growth disadvantage proliferate to a lesser extent,thereby repopulating the liver or other organ with the ex vivo cells.Where the ex vivo cells are sensitive the growth disadvantagingproperties of the agent that confers a growth disadvantage to at least asubset of the endogenous cells of the organ, step (a) is performedbefore step (c). Otherwise steps (a), (b) and (c) may be performedconcurrently or in any order. With a preferred order having step (a)being performed first and then step (b) followed by step (c), or steps(b) and (c) being performed concurrently, or step (c) being performedbefore step (b). In yet other embodiments, there is the further step,after steps (a) to (c), of transplanting the ex vivo cells into a humansubject. In embodiments, the ex vivo cells are adult somatic cells,adult progenitor cells, adult stem cells, embryonic progenitor cells, orembryonic stem cells which can differentiate into a parenchymal cell ofthe host organ or (in the case of a heterotopic engraftment) of anotherorgan whose functional activity is deficient in the host. In still otherembodiments, the ex vivo cells are heterologous to the subject. In someembodiments, the ex vivo cells are human. In still other embodiments,the ex vivo cells are autologous, allogeneic, or xenogenic to thesubject. In additional embodiments, the ex vivo cells are the same celltype as an endogenous cell type of the organ or heterologous to theorgan. In other embodiments, the ex vivo cells are not an endogenouscell type of the organ and are cultured prior to administration. In someembodiments, the ex vivo cells express a heterologous nucleic acid forgene therapy. In other embodiments, the ex vivo cells have beengenetically modified to eliminate a gene or to increase or decrease theexpression of a protein. In still another embodiment, the ex vivo cellis an immortalized cell. In other embodiments of any of the above, theex vivo cell is optionally further modified to contain genes whoseexpression is under the control of a promoter sensitive to a specificagent (drug, compound, heat, radiation) wherein the genes so controlledexpress a protein functioning as a maker or modulating cell function,cell growth, cell replication, apoptosis, or survival. The heterologousnucleic acid may express a protein needed by the subject. The organ maybe damaged or healthy. In some embodiments of any of the above, the exvivo cells are liver cells and the target organ is the liver. Thesubject can be a human or a mammal (e.g., a non-human primate (e.g., achimpanzee, baboon, macaque), a rodent (e.g., a mouse, a rat) a pig, arabbit). In instances, where the ex vivo cells are antigenicallydifferent from the host, immunosuppressive therapy may be furtheradministered. In further embodiments of the above, the inventionprovides a preparative regimen of hepatic irradiation and hepaticmitotic signals, such as, hepatocyte growth factors to grow adultprimary human hepatocytes or human stem cells in a non-human liver.Development of chimeric immunodeficient or tolerized immunocompetent(non-human mammals (e.g., mice, SCID mice, nude mice) with human livercells or human stem cells is contemplated wherein such mice can be usedas a source of human origin cells (e.g., stem and parenchymal cells) forex vivo transplants in humans in need thereof.

The agent that confers a growth disadvantage to at least a subset ofendogenous cells of the engraftment site or damaged organ can beionizing radiation (e.g., X-rays, gamma rays, ARC therapy, TOMO therapy,particle therapy, electron therapy, proton therapy, carbon ion therapy),cytotoxic chemicals, ultrasound, heat, biological agents, degenerativeproteins, or proteins that suppress cell division. The mitogeniccomposition can be a mammalian growth factor (e.g., HGF, EGF, FGF, VEGF,NGF, Il-6, TNF-alpha, CTNF, R-spondin 1, Noggin, and TWEAK). In someembodiments, the agent is partial liver irradiation (e.g., using 3-Dconformal RT). For instance, hepatic irradiation can be delivered toportions of the liver while other portions are shielded (e.g., the rightanterior lobes of the liver can be irradiated after shielding the leftanterior and right posterior and caudate lobes using lead shields). Theradiation in other embodiments is SRS, Intensity-Modulated RadiationTherapy (IMRT), dynamic adaptive radiation therapy, or image-guidedradiation therapy (IGRT).

With respect to the liver, preparative hepatic irradiation can be usedto facilitate stem cell/liver cell transplantation for i) the treatmentof inherited liver diseases, ii) liver failure, iii) ex vivo hepaticgene therapy, iv) rescuing patients with liver cancer, followingchemotherapy or radiation therapy, and v) expanding human hepatocytes inanimal liver for generating animal models for human-specific hepaticinfections and human hepatic responses to hepatoxic agents, metabolismof drugs, or the response of the human liver to therapeutic treatmentsin various disease states (e.g., infection (e.g., HCV, HBV), toxicity).

Accordingly, in some embodiments, the invention provides a method ofobtaining an expanded population of ex vivo cells by (a) administeringto a non-human mammalian subject an effective amount of an agent thatconfers a growth disadvantage to at least a subset of endogenous cellsat a site of engraftment; (b) administering to the non-human mammaliansubject an effective amount of a mitogenic stimuli for the ex vivocells; and (c) administering the ex vivo cells to the subject, whereinthe ex vivo cells engraft at the site and proliferate to a greaterextent than the subset of endogenous cells, thereby repopulating atleast a portion of the engraftment site with the ex vivo cells, and (d)harvesting the repopulated cells from the engraftment site; therebyobtaining the expanded ex vivo cell population. In some of theseembodiments, the ex vivo cells are human. In other further embodiments,the ex vivo cells are selected from the group consisting of adultsomatic cells, adult progenitor cells, adult stem cells, embryonicprogenitor cells, fetal cells, xenogenic cells, and embryonic stemcells. In some embodiments, the ex vivo cells heterologous to thenon-human subject. In yet other embodiments, the agent that confers agrowth disadvantage to at least a subset of endogenous cells of theorgan is radiation (e.g., x-ray and gamma ray). In still another furtherembodiment, the agent that confers a growth disadvantage to at least asubset of endogenous cells of the engraftment site is selected from thegroup consisting of cytotoxic chemicals, ultrasound, heat, biologicalagents, degenerative proteins, and proteins that suppress cell division.In additional further embodiments, the mitogenic stimulus comprises oneor more (e.g., 1, 2, 3. or 4) growth factors selected from the groupconsisting of HGF, EGF, FGF, VEGF, NGF, Il-6, TNF-alpha, CTNF, R-spondin1, Noggin, and TWEAK. In still additional further embodiments, the exvivo cell is derived from brain, intestinal, or liver tissue.

In a further related aspect, the invention provides a method of treatinga subject having a damaged organ or tissue or an organ or tissue withreduced function by engrafting cells obtained by the above methods. Insome embodiments, the organ is intestine, liver, lung, kidney, pancreas,eye, testes, brain, ovary, or skin. In another aspect accordingly, theinvention provides a chimeric non-human animal and methods of makingsuch an animal as described above which has greater than 50, 60, 70percent or near total replacement (e.g., 80, 85, 90, 95, 98 per cent) ofits host organ by engrafted ex vivo cells (e.g, a host liver repopulatedwith 50, 60, 70 percent, or near total replacement by, human primaryhepatocytes or human organ specific stem cells).

In another aspect, the invention provides a method of treating amammalian subject having a damaged central nervous system (e.g., brain,spinal cord) with a reduced function by engrafting mammalian ex vivocells at the site of injury, by (a) administering to the subject aneffective amount of an agent that increases the engraftment of ex vivocells at the site of injury; (b) optionally administering to the subjectan effective amount of a mitogenic stimuli for the ex vivo cells; and(c) administering the ex vivo cells to the subject, wherein the ex vivocells engraft at the site of injury and repopulate at least a portion ofthe site with the ex vivo cells, wherein the repopulated ex vivo cellssupplement the function, thereby treating the subject. In this aspect,the ex vivo cells can be selected from the group consisting of adultsomatic cells, adult neuron progenitor cells, adult stem cells,embryonic progenitor cells, fetal cells, xenogenic cells, and embryonicstem cells which are capable of populating the site of injury withneurons.

In another aspect, the invention provides methods for the isolationand/or purification of HPCs from donor livers by selecting cellstherefrom for the presence of the EpCAM marker. Accordingly, in someembodiments, above aspects and embodiments of the invention employ HPCswhich have been selected for or sorted according to the presence of theEpCAM marker.

Abbreviations

ALT, Alanine transaminase

AST, Aspartate transaminase

ATP, Adenosine tri-phosphate

BrdU, bromodeoxyuridine

CRT, conformal radiation therapy

DCF, 2′,7′-dichlorofluorescin diacetate

DPPIV, Dipeptidyl peptidase IV

F344, Fischer 344 rats

GGT, γ-glutamyl transpeptidase

HGF, Hepatocyte Growth factor

HIR, Hepatic irradiation

HT, Hepatocyte transplantation

IR, ionizing radiation

LDH, Lactose dehydrogenase

OLT, Orthotopic Liver Transplantation

PET, Positron emission tomography

PH, Partial hepatectomy

PVBL, Portal vein branch ligation

RILD, radiation-induced liver disease

RT, Radiation therapy

SRS, Stereotactic radiosurgery

T3, tri-iodo-thyronine

UGT1A1, bilirubin-UDP-glucuronosyltransferase

VOD, veno-occlusive disease

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1A-1F. HT ameliorates histomorphological changes of RILD. FIG. 1A,hepatocellular loss around central veins (C) in rats receiving PH+HIR at2 weeks. FIG. 1B, centrizonal steatosis in PH+HIR rats at 1 week. FIG.1C, amelioration of perivenous hepatocellular loss and steatosis after 1week of HT. FIG. 1D and FIG. 1E, Extensive proliferation of oval cellsand bile duct proliferation extending from portal tract (P) in PH+HIRrats at 17 weeks. FIG. 1F, amelioration of bile duct proliferation andfibrosis in transplanted rat at 17 weeks.

FIG. 2. HT Improves survival in rats that received PH+HIR. Kaplan-Meieranalysis of survival shows improved survival (P=0.02, log-rank test) ofPH+HIR -treated rats after HT versus PH+HIR alone.

FIGS. 3A-3D. DPPIV staining of livers. FIG. 3A (x4) and FIG. 3B (x320),PH+HT. FIG. 3C (x2) and FIG. 3D (x320), PH+HIR+HT. Note the near-totalreplacement of the irradiated host liver by DPPIV+ve transplanted cells(red stain) 12 weeks PH+HIR+HT.

FIGS. 4A-4E. Complete long-term normalization of serum bilirubin levelsby extensive repopulation of Gunn rat (GR) liver by normal hepatocytes,transplanted after PH+HIR. Results shown are 5 months after HT in GRtreated with PH+HIR. FIG. 4A. UGT1A1 immunoblot analysis of GR liverhomogenates. Note the presence of UGT1A1 band in GR treated with PH+HIR.FIGS. 4B-D. UGT1A1 immunohistochemical staining of liver sections-B,Wistar-RHA; C, GR; D, GR after PH+HIR+HT. FIG. 4E. Serum bilirubinlevels after HT in Gunn rats receiving PH (n=4, □), HIR (n=4, ), orHIR+PH (n=9, Δ).

FIGS. 5A-5E. Extensive liver repopulation by DPPIV+ve hepatocytes) inlivers of DPPIV−ve F344, congeneic rats, that were subjected toHIR+PVBL. Selective ligation of the portal venous branch results intheir atrophy and induction of regeneration in the residual lobes. Theright branch of the portal vein was ligated, followed by irradiation ofthe anterior liver lobes after blocking the right posterior and thecaudate lobes in DPPIV−ve F344 rats. Note selective repopulation of theanterior lobes (median and right anterior) by the transplanted cells inthese animals (FIGS. 5B-E, Anterior lobe; FIG. 5F, Caudate lobe). FIG.5A, blanching and apoptosis of right median lobe 48 hours after PVBL.FIG. 5B. Anterior lobes at 3 weeks. FIG. 5C. Anterior lobes at 3 months.FIG. 5D. Anterior lobes 5 months. FIG. 5E. DPPIV histochemistry ofmedian lobe 5 months after PVBL+HR+HT (2x). Note the near totalreplacement of the host hepatocytes with transplanted DPPIV+ve cells.FIGS. 5B to E. Selective lobar repopulation of transplanted hepatocytesafter right middle vein branch ligation (PVBL)+ partial liverirradiation (anterior lobes) HIR. Note minimal repopulation in theposterior lobes that were shielded from HIR. F. Posterior Lobe 5 months.

FIGS. 6A-6G. Preparative regimen of HIR (50 Gy)+Tri-iodothyronine (T3)(400 μg/day subQ, every 10 days after HT). FIG. 6A, Extensiverepopulation in Gunn rats. FIG. 6B, Normalization of serum bilirubin inGunn rats after HIR+T3+HT. Note that HT after HIR or T3 alone fails tonormalize the serum bilirubin. FIG. 6C, T3 induces DNA synthesis inliver cells, which is not suppressed by inderal. FIGS. 6D-E, Extensiveliver repopulation after T3+HIR. FIGS. 6F-G, Moderate liver repopulationafter T3+Inderal+HIR. This regimen could be clinically useful, as itallows hepatocyte repopulation without the cardiac side effects oftachycardia produced by T3.

FIGS. 7A-7D. HT following HIR and systemic administration of recombinantadenovirus expressing human Hepatocyte Growth (HGF). Beta-Gal+ve Rosahepatocytes were transplanted in congeneic C57B1/6 mice that receivedHIR (50 Gy)+Adeno-HGF injection. Histochemical staining of frozen liversections for beta-galactosidase 2 (a), 4 (b), 8 (c) and 20 (d) weeksafter HT.

FIGS. 8A and 8B. Focal HIR promotes selective lobar repopulation. FIGS.8A Repopulation of beta-gal+ve Rosa transplanted hepatocytes inirradiated anterior lobe as compared to shielded posterior lobe. FIG.8B. A single liver lobe or a portion of the Right anterior lobe inC57B1/6 mice after a regimen of regional/focal HIR+Ad-HGF.

FIGS. 9A-9C. Ex vivo UGT1A1 gene therapy in Gunn rats. FIG. 9A.Experimental design. FIG. 9B. UGT1A1 immuno-histochemistry demonstratingprogressive repopulation of liver lobes by UGT1A1-transduced hepatocytesfollowing PH+HIR at pretransplant, 2 weeks, 4 weeks, 8 weeks, and 16weeks. FIG. 9C. Complete correction of serum hyperbilirubinemia in Gunnrats after ex vivo gene therapy and transplantation of autologous,conditionally immortalized hepatocytes.

FIGS. 10A-10D. Transplanted liver stem cells (oval cells, OC)differentiate into hepatocytes and bile ducts in rat livers treated withHIR and Ad-HGF. FIG. 10A: y-GGT staining on isolated oval cells beforetransplantation, FIGS. 10B-D: DPPIV histochemistry of fresh frozen liversections of F344 rats treated with HIR and Ad-HGF, 6 weeks after ovalcell transplantation. FIG. 10C, DPPIV+ve bile duct. FIGS. 10B and D,DPPIV+ve hepatocytes.

FIGS. 11A-11F. Liver stem cells (oval cells, OC) proliferate andrepopulate irradiated median lobes of rats treated with partial HIR(median lobe) and Ad-HGF. FIGS. 11A-C, Liver repopulation in irradiatedmedian lobes; FIG. 11D-F, engraftment of oval cells without liverrepopulation in caudate lobes that were shielded and not irradiated.Note cell-cell competition between non-irradiated OC and irradiated hosthepatocytes.

FIGS. 12A-1I1. Liver stem cells (oval cells) engraft but fail toproliferate in rats that received oval cell transplantation aftertreatment with either HIR alone (FIGS. 12A-C) or Ad-HGF alone (FIGS.12D-F) or oval cell transplantation without any preparative regimen(FIGS. 12G-I).

FIG. 13. Isolation of EpCAM+ve liver stem cells (oval cells) withmagnetic beads. Immunocytochemistry with EpCAM and CK19.

FIGS. 14A and 14B. EpCAM+ve liver stem cells proliferate and repopulateirradiated median lobes of rats treated with partial HIR (median lobe)and Ad-HGF. DPPIV histochemistry demonstrating DPPIV+ve transplanteddonor hepatocytes in DPPIV−ve host liver.

FIGS. 15A-15D. Development of bile duct cancer after transplantation ofliver stern cells (oval cells) in rats that received partialhepatectomy, Gross (FIG. 15A) anterior view, (FIG. 15B) posterior viewof livers transplanted with liver cancer stem cells. (FIG. 15C), (FIG.15D). Microscopic views of recipient liver after HE staining. (c-10X,d-20X). RAL: right anterior lobe.

FIGS. 16A-16D. Development of bile duct cancer after transplantation ofliver stem (oval cells) in rats that received partial hepatectomy. DPPIVstaining of recipient liver five weeks after partial hepatectomy andoval cell transplantation. Long arrows: strong DPPIV+gland-likestructure. Short black arrow: weak DPPPIV-gland-like structure. Whitearrow: DPPEV−gland-like structure.

DETAILED DESCRIPTION OF THE INVENTION

Our experiments demonstrate that parenchymal cell transplantation is ofbenefit in ameliorating radiation injury and other injury to organs.FIGS. 1D-E demonstrates parenchymal cell transplantation can modulatethe late effects of RT. Accordingly, cell transplantation can replacethe loss of parenchymal cells due to radiation or other injury oforgans. In our RILD model of PH+HIR in rats, we observed that adultliver stem cells (a.k.a oval cells) proliferate extensively and attemptto restore the parenchymal cell loss caused by PH and HIR. Therefore, itwas contemplated that adult progenitor cells or stem cells can engraftin injured organs, such as, liver and can differentiate intoorgan-specific parenchymal cells. Thus a preparative regimen of focalirradiation, delivered by SRS or IMRT, can serve to ablate parenchymalcells in various organs and create a microenvironment that promotes theengraftment, growth and differentiation of progenitor/stem cell in vivo.The irradiation is thought to increase the engraftment by inhibiting theproliferation of endogenous cells, thereby leaving ‘room’ for theengrafted cells to grow.

The liver was used as our primary model organ. Adult liver cells(hepatocytes) have remarkable regenerative potential and haveextensively repopulated rodent livers on serial transplantation(Overturf, K. et al., Am J Pathol, 151:1273-1280 (1997)). However,shortage of donor hepatocytes and inability to grow primary hepatocytesin culture have triggered a search for progenitor cells that can begrown in culture and cryopreserved in “cell banks” for future use.Accordingly, in exemplary embodiments where the liver is the targetorgan, the ex vivo cells are hepatic progenitor/stem cells—fetalhepatocytes, amniotic epithelial cells, “oval” cells and “small”hepatocytes. Fetal hepatocytes can differentiate into primaryhepatocytes after intraportal cell transplantation. It is contemplatedthat the amniotic epithelial cells can maintain the plasticity ofpregastrulation embryo cells and have the potential to differentiate toall three germ layers. Miki et al has recently demonstrated thatamniotic epithelial cells isolated from human term placenta expresssurface markers normally present on embryonic stem and germ cells (Miki,T. et al., Stem Cells, 23:1549-1559 (2005)). In addition, amnioticepithelial cells express the pluripotent stem cell-specifictranscription factors octamer-binding protein 4 (Oct-4) and nanog andcan form spheroids that retain stem cell characteristics under certainculture conditions. They further demonstrate that amniotic epithelialcells do not require other cell-derived feeder layers to maintain Oct-4expression, do not express telomerase, and are nontumorigenic upontransplantation. Based on immunohistochemical and genetic analysis,amniotic epithelial cells have the potential to differentiate to allthree germ layers-endoderm (liver, pancreas), mesoderm (cardiomyocyte),and ectoderm (neural cells) in vitro. Thus, amnion derived from termplacenta after live birth may be a useful and noncontroversial source ofstem cells for cell transplantation and regenerative medicine.Accordingly, in one embodiment, the ex vivo cell is a amnioticepithelial cells which has the potential to engraft, differentiate andrepopulate the host liver and rescue it from radiation injury.

Adult hepatic progenitor/stem cells (a.k.a. “oval” cells) expand duringliver injury, such as, in alcoholic liver injury, and submassiveparenchymal necrosis as well as experimental injury models featuringblocked hepatocyte replication, such as, after HIR. Oval cells canpotentially become either hepatocytes or biliary epithelial cells andmay be critical to liver regeneration, particularly when hepatocytereplication is impaired. Recently, it was reported that a TNF familymember called TWEAK (TNF-like weak inducer of apoptosis) stimulates ovalcell proliferation in mouse liver through its receptor Fn14 (Jakubowski,A. et al., J Clin Invest, 115:2330-2340 (2005)). Accordingly, in oneembodiment, liver is treated with ex vivo “oval” cells and optionally,TWEAK is the mitogenic agent administered to rescue hepatic radiationinjury by stimulating the proliferation of the transplated “oval” cells.

Finally, a “small hepatocyte” (SH) fraction has been described to have abetter replicative potential than adult parenchymal hepatocytes (PaH)(Tateno, C. et al., Hepatology, 31:65-74 (2000); Katayama, S. et al., AmJ Pathol, 158:97-105 (2001)). SH can be isolated from the supernatant orthe nonparenchymal component of collagenase-perfused rat liver. Inexperiments, we examined whether SH can repopulate faster than PaH.Extensive studies have been performed to evaluate the growth potentialof a small hepatocyte population (≦16 μm diameter) (Lemire, J. et al.,American Journal of Pathology, 139:535-552 (1991)) isolated from thenon-parenchymal fractions of collagenase-perfused livers (Kubota, H. etal., Proc Natl Acad Sci USA, 97:12132-12137 (2000); Sigal, S. et al.,Hepatology, 19:999-1006 (1994); Sigal, S. et al., Differentiation,59:35-42 (1995); Taniguchi, H. et al., Cell Transplant, 9:697-700(2000); Yin, L. et al., Hepatology, 35:315-324 (2002); Suzuki, A. etal., Hepatology, 32:1230-1239 (2000); Fujikawa, T. et al., J Hepatol,39:162-170 (2003)). These cells could proliferate in cell culture(Tateno, C. et al., Hepatology, 31:65-74 (2000), Tateno, C. et al., Am JPathol, 149:1593-1605 (1996); Tateno, C. et al., Am J Pathol,148:383-392 (1996); He, Z. et al., Differentiation, 71:281-290 (2003);Ikeda, S. et al., J Hepatol, 37:7-14 (2002)) and retained theirproliferative capacity following long-term cryopreservation (Ikeda, S.et al., J Hepatol, 37:7-14 (2002)). It was reported that these cellshave a higher proliferative capacity than adult parenchymal hepatocytesin the retrorsine+PH model of liver repopulation Katayama, S. et al., AmJ Pathol, 158:97-105 (2001). In the context of clinical application,livers from adult donors contain very few oval cells, but a largernumber of small hepatocytes can be isolated from the liver by Percollgradient fractionation of liver cells. Our studies indicate that smallhepatocytes may indeed have a better replicative potential than adultparenchymal hepatocytes (Section c. 4.4, FIG. 9). Accordingly, in oneembodiment where the liver is the target organ, the ex vivo cells are SHcells.

Definitions:

Unless otherwise stated, the following terms used in the specificationand claims have the meanings given below.

It is noted here that as used in this specification and the appendedclaims, the singular forms “a,” “an,” and “the” include plural referenceunless the context clearly dictates otherwise.

Ex vivo cells—A mammalian cell capable of repopulating the host organ.They can be freshly harvested cells, cultured cells, and/or geneticallytransformed to provide a genetic marker, correct a genetic defect in theex vivo cell (as in the case of some autologous ex vivo cells), or toincrease or modulate their ability to proliferate when engrafted or inculture. In some embodiments, the host organ acts as a culture mediumfor the ex vivo cells. In some further embodiments, the cultured ex vivocells can later be harvested for study or engraftment to anotherindividual. In some embodiments, the ex vivo cell is a cell type whosefunction and/or number is deficient in the host organ. In someembodiments, the ex vivo cells is of the same cell type as that of thecell whose number or function is deficient in the host organ. In someembodiments, the ex vivo cell is a cell which can differentiate intosuch a cell. In some embodiments, the ex vivo cell is a cultured cell(e.g., one that can be passaged at least 25 or 50 times in culture). Theex vivo cell can be derived from the subject or another individual oranother species. The ex vivo cell can be cultured to increase itspopulation. In some embodiments, the cell is treated ex vivo to enhancea biological property (rate of mitosis, gene therapy) before beingadministered to the subject or engrafted onto the host. Ex vivo cellsharvested from the host organ or host may be the subject of gene therapyand subsequently cultured to expand their population and then engraftedinto or upon the host organ. Accordingly, the ex vivo cells can be adultsomatic cells, adult progenitor cells, adult stem cells, embryonicprogenitor cells, fetal cells, cord blood cells, xenogenic cells, orembryonic stem cells. The ex vivo cells can be fetal hepatocytes,amniotic epithelial cells, “oval” cells and “small” hepatocytes. Instill other embodiments, the ex vivo cells are heterologous to thesubject. In still other embodiments, the ex vivo cells are autologous tothe subject. In additional embodiments, the ex vivo cells are the samecell type as an endogenous cell type of the organ or heterologous to theorgan. In other embodiments, the ex vivo cells are not an endogenouscell type of the organ. The ex vivo cells can be cultured prior toadministration. In some embodiments, the ex vivo cells express aheterologous nucleic acid for gene therapy. In some embodiments, thegrafted cells repopulate the damaged organ with healthy cells of thesame type and/or function as those whose growth was targeted to bedisadvantaged, or disadvantaged, by administration of the agent thatconfers a growth disadvantage. In some embodiments, the cells are bonemarrow progenitor cells, embryonic stem cells, neural progenitor cells,endothelial progenitor cells, progenitor cells obtained from peripheralblood, cord blood cells, amniotic epithelial cells, fetal cells,organ-specific stem cells, such as, oval cells, primary hepatocytes,primary parenchymal cells, human umbilical microvascular endothelialcells, blood outgrowth endothelial cells, glia, or human brainmicrovascular endothelial cells. In one embodiment, the ex vivo cellline is a highly differentiated immortalized human hepatocytes cell line(e.g., a highly differentiated immortalized human hepatocyte line withsimian virus 40 large tumor antigen for liver based cell therapy, see,Li et al., ASAIO J. 51(3):262-8 (2005). Human progenitor liverepithelial cells with extensive replication capacity and differentiationinto mature hepatocytes are also suitable (see, Yin et al., Stem Cells20:338-346 (2002)). In some instances, an ex vivo cell (e.g., a stemcell) may fuse with an endogenous hepatocytes to provide the repopulatedcell. The ex vivo cells may be administered locally or systemically. insome embodiments, the ex vivo cells are cryopreserved and stored forlater use.

For instance, the ex vivo cells can be tissue stem cells which have thecapacity to self-renew and are capable of producing progeny in at leasttwo lineages. They can also be capable of long-term tissuereconstitution and serial transplantability.

Oval cells are liver stem cells which can either give rise to bile ductcells (cholangiocytes) or liver cells (hepatocytes). Whether or not thecells become cholangiocytes or hepatocytes depends on thepathophysiological circumstances they were grown under. Oval cells canbe cryopreserved, stored and grown later.

In some embodiments, the ex vivo cells are bone marrow progenitor cells,embryonic stem cells, neural progenitor cells, endothelial progenitorcells, progenitor cells obtained from peripheral blood, cord bloodcells, amniotic epithelial cells, fetal cells, organ-specific stemcells, such as, oval cells, primary hepatocytes, primary parenchymalcells, human umbilical microvascular endothelial cells, blood outgrowthendothelial cells, glia, or human brain microvascular endothelial cells.

In some embodiments, the ex vivo cell expresses a protein or polypeptidenot normally expressed by the host tissue at the engraftment site andthis protein is used as a label to detect the ex vivo cells. In someembodiments, the ex vivo cells are modified ex vivo to express a proteinor provide a nucleic acid not normally expressed by the host or bytissues of the engraftment site or by the damaged organ or organ havinga reduced function. In some embodiments, the modification introduces agene which is expressed in other tissues of the host but which is notnormally expressed at the engraftment site tissue or by the damagedorgan. In some embodiments, the gene expresses creatine kinase and thedamaged organ is the liver. The protein or nucleic acid can serve as alabel by which the ex vivo cells and their progeny can be detected inthe host. In some embodiments, the protein can be a fluorescent proteinnot otherwise expressed in the host. Detection of the ex vivo cells canbe used to monitor the progress of the engraftment and to further adjustthe regimens used to administer the agents which confers a growthdisadvantage and/or mitogenic stimulus or to further administeradditional ex vivo cells. A preferred method of evaluating host organ orengraftment site repopulation is taught by Landis et al., Hepatology44:1250-1258 (2006), which is incorporated by reference in its entirety.This method discloses the use of magnetic resonance spectroscopicimaging detect ex vivo cells. Accordingly, in some embodiments, the exvivo cells are detected using MRSI to detect substrates or products ofreactions suitable for such imaging methods which are produced byenzymes which are differentially expressed by the ex vivo cells asopposed to the engraftment site tissues or damaged organ (e.g., ³¹Pmagnetic resonance spectroscopic imaging of liver engrafted with cellsexpressing creatine kinase). In some embodiments, the label is nototherwise expressed in the host and can be used to target the ex vivocell for destruction by use of an antibody directed toward the proteinin the event the ex vivo cells prove harmful to the host. Preferably, inthis embodiment, the protein is expressed on the cell surface of the exvivo cell. Methods of genetically modifying cells or making recombinantcells are well known to persons of ordinary skill in the art.

“Endogenous” cells are cells originating from the host and found in thetarget organ which may compete with ex vivo cells following theirintroduction for repopulating the organ.

The term “recombinant” when used with reference, e.g., to a cell, ornucleic acid, protein, or vector, indicates that the cell, nucleic acid,protein or vector, has been modified by the introduction of aheterologous nucleic acid or protein or the alteration of a nativenucleic acid or protein, or that the cell is derived from a cell somodified. Thus, for example, recombinant cells express genes that arenot found within the native (non-recombinant) form of the cell orexpress native genes that are otherwise abnormally expressed, underexpressed or not expressed at all. In some embodiments according to theinvention, the ex vivo donor cell has been modified by the introductionof a heterologous nucleic acid or protein or the alteration of a nativenucleic acid or protein, or that the cell is derived from a cell somodified.

“Engraft” means to become established as a living part or attachment ofa host organ. The graft may be orthotopic or heterotopic to the hostorgan.

Proliferation references the rate of cell division or multiplication andincrease of cell number.

“Autologous” references biological mater derived from tissues or DNA ofthe subject or host. The ex vivo cells can be autologous.

“Heterologous” references biological matter derived from the tissues orDNA of a different species or different individual of the same speciesas the subject or host (e.g., allogenic or xenogenic). The ex vivo cellscan be heterologous.

Agents that confer a growth disadvantage do not necessarily kill thecell, but competitively disadvantage the growth of the cell with respectto the engrafted ex vivo cells. The disadvantage is with respect tocellular proliferation rates and/or the ability of the endogenous cellsto compete with the ex vivo cells in populating a host organ or survive.Such agents can be ionizing radiation, heat, ultrasound, LASAR,cytotoxic chemicals (preferably toxic chemicals which are selectivelytoxic for the endogenous cells of the target organ, and moreparticularly, the endogenous cells of the type to be repopulated.Ultrasound, focused ultrasound, focused ultrasound targeted by magneticresonance imaging of the target site temperature, biological agents(viruses); cell growth suppressors. The agents may be cytostatic orcytotoxic. They may be biological agents, nucleic acids (e.g., siRNA)proteins (e.g., antibodies or polypeptides), drugs or small moleculesthat suppress cell division. Preferably, growth or cell proliferation ofthe endogenous cells can be reduced by at least 50%, 75%, 80%, 90%, 95%or 98% (or any range therebetween) of the rate observed for endogenouscells not so treated. The agents may be administered locally orsystemically.

Mitogenic composition or mitogenic stimulus refer to subject matter thatstimulates cell division such as a growth factor. One or more stimulican be used. The stimulus can be a mitogen, chemokine, cytokine, hormoneor agents which acts similarly on their receptors (e.g., antibodies).Preferred mitogens may be tissue specific and/or at least stimulate theex vivo cell type to be engrafted. Suitable mitogens include mammaliangrowth factor (e.g., HGF, EGF, FGF, VEGF, NGF, Il-6, TNF-alpha,circulating tumour necrosis factor (CTNF), R-spondin 1, Noggin, andTWEAK, growth receptor ligand) and c-met activating antibody. EGFpromotes proliferation of mesenchymal, glial and epithelial cells. NGFpromotes neurite outgrowth and neural cell survival. FGF promotesproliferation of many cells; inhibits some stem cells; induces mesodermto form in early embryos. FGF has at least 19 family members and 4distinct receptors. Additional suitable mitogens include PDGF whichpromotes proliferation of connective tissue, glial and smooth musclecells and has two different different protein chains forming 3 distinctdimer forms; AA, AB and BB; insulin-like growth factor-I (IGF-I) whichpromotes proliferation of many cell types and is related to Insulin-likegrowth factor-II (IGF-II) and proinsulin, also called Somatomedin C; andIGF-II which promotes proliferation of many cell types primarily offetal origin. The factors may be wild-type (e.g, human, primate, murine,rat, etc.) or substantially identical to the wild-type factor.Preferably, cell growth rates are increased by at least 1.5-fold,2-fold, 3-fold, 4-fold, or 6-fold (or any range therebetween). Thecompositions or stimuli may be administered locally or systemically.PDGF promotes proliferation of connective tissue, glial and smoothmuscle cells. Two different protein chains form 3 distinct dimer forms;AA, AB and BB. Osteoinductive molecules are one or more of thefollowing: BMP-1, BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, BMP-7, BMP-8,BMP-9, BMP-10, BMP-11, BMP-12, BMP-13, BMP-14, BMP-15 and BMP-16. Thestimulus may be a heterologous gene that increases their intrinsicproliferation capacity or survival. The mitogenic stimulus may comprisea biological agent, antibody or peptide factor that increases theproliferation capacity of the donor cells or a procedure thatdeliberately injures the engraftment site to make “space” for theengrafted ex vivo cells and/or to provide a compensatory growth signalfor the ex vivo cells.

“Repopulate” means that the engrafted ex vivo cells grow to provide orreplace at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95%(or any range represented therebetween) of the cells of the damagedorgan. The cells to be replaced may be of the same tissue type as theengrafted cells. “Repopulate” also references a cell population which issufficient in number and activity to ameliorate a condition associatedwith the damage to the organ or improve a homeostasis (e.g., metabolismof glucose, ammonia, blood lipids, etc.) originally impaired by thedamage to the organ. The repopulation by the ex vivo cells typically canprovide organ specific parenchymal cells. The ex vivo cell can behomologous or heterologous to the organ.

“Effective amount” or “effective dose” or “therapeutically sufficient oreffective amount or dose” and the like reference a dose of an agent,mitogenic compound, or ex vivo cell that produces the intended effectfor which it is administered. The exact dose will depend on the purposeof the treatment, and can be ascertainable by one skilled in the artusing known techniques. An intended effect of the agent which confers agrowth disadvantage on the endogenous cells is just that. An intendedeffect of a mitogen is to repopulate the target organ with the ex vivocells. An intended effect of the ex vivo cell is to restore or maintaina homeostasis effected by the target organ. Methods of tracing theorigin of cell populations and assessing homeostatis are well known inthe transplantation and clinical arts.

An “organ” is a group of tissues that perform a specific function orgroup of functions. Usually there are main tissues and their cell typesthat uniquely predominate for the specific organ and sporadic tissuesand cell types. For example, in the brain the main tissues are neuronsand glia and sporadic tissues include the blood and endothelium of theblood vessel wall. Organs which may be treated according to theinvention include the lungs, brain, eye, skin, stomach, spleen, bone,pancreas, kidneys, liver, intestines, skin, uterus, and bladder,prostate, ear, and testes. An exemplary organ according to the inventionis the liver. Accordingly, the ex vivo cells can repopulate an organ toprovide cells of a desired type including those of the followingtissues: bone, cartilage, ligament, tendon, heart, liver, kidney, brain,skin, cartilage, bladder, lung, thymus, thyroid, spinal cord, pancreas,skin, gut, bowel, blood vessels, bladder, joint cartilage,intervertebral disc, ligament, tendon, meniscus, or pancreas.

A “damaged organ” or “organ having a reduced function” is one which haslost a substantial portion of its biological functioning and/or mass dueto the damage. The damage can be due to trauma, surgery, infection,cancer, congenital or genetic condition, or a chemical exposure. Thedamage may relate to the ability to provide a needed product (e.g.,glucose, insulin, secretion, signal) or function (e.g., metabolizedrugs, motility, filtration, excretion). In some embodiments, there is aproviso that the damage to be treated is one which was not itself causedby exposure to the agent to be used to confer the growth disadvantage.In other embodiments, there is a proviso that the damaged organ is notthe pancreas and/or bone marrow. One of ordinary skill in the clinicalart can recognize a subject having a damaged organ or an organ having areduced function and who, accordingly, would benefit from treatmentsaccording to the invention. Further, one of ordinary skill in theclinical arts can ascertain when a function impaired by the damage tothe host organ or tissue has been ameliorated, improved, or restored byuse of appropriate clinical endpoints.

A “host” or “target” organ is one to be populated or repopulated with exvivo cells. It may be the same organ type from which the ex vivo cellswere derived or different. For instance, ex vivo hepatocytes may beengrafted onto the spleen. In an exemplary embodiment, the host organ isthe liver, and the ex vivo cells are capable of repopulating the liverwith hepatocytes.

A subject references a mammal and includes human and non-human animals(e.g., primates, rodents, lagomorphs, pigs). An exemplary subject is thehuman.

The terms “polypeptide,” “peptide” and “protein” are usedinterchangeably herein to refer to a polymer of amino acid residues. Theterms apply to amino acid polymers in which one or more amino acidresidue is an artificial chemical mimetic of a corresponding naturallyoccurring amino acid, as well as to naturally occurring amino acidpolymers and non-naturally occurring amino acid polymer. Methods forobtaining (e.g., producing. isolating, purifying, synthesizing, andrecombinantly manufacturing) polypeptides are well known to one ofordinary skill in the art.

The term “amino acid” refers to naturally occurring and synthetic aminoacids, as well as amino acid analogs and amino acid mimetics thatfunction in a manner similar to the naturally occurring amino acids.Naturally occurring amino acids are those encoded by the genetic code,as well as those amino acids that are later modified, e.g.,hydroxyproline, γ-carboxyglutamate, and O-phosphoserine. Amino acidanalogs refers to compounds that have the same basic chemical structureas a naturally occurring amino acid, i.e., an α carbon that is bound toa hydrogen, a carboxyl group, an amino group, and an R group, e.g.,homoserine, norleucine, methionine sulfoxide, methionine methylsulfonium. Such analogs have modified R groups (e.g., norleucine) ormodified peptide backbones, but retain the same basic chemical structureas a naturally occurring amino acid. Amino acid mimetics refers tochemical compounds that have a structure that is different from thegeneral chemical structure of an amino acid, but that functions in amanner similar to a naturally occurring amino acid.

Amino acids may be referred to herein by either their commonly knownthree letter symbols or by the one-letter symbols recommended by theIUPAC-IUB Biochemical Nomenclature Commission. Nucleotides, likewise,may be referred to by their commonly accepted single-letter codes.

As to “conservatively modified variants” of amino acid sequences, one ofskill will recognize that individual substitutions, deletions oradditions to a nucleic acid, peptide, polypeptide, or protein sequencewhich alters, adds or deletes a single amino acid or a small percentageof amino acids in the encoded sequence is a “conservatively modifiedvariant” where the alteration results in the substitution of an aminoacid with a chemically similar amino acid. Conservative substitutiontables providing functionally similar amino acids are well known in theart. Such conservatively modified variants are in addition to and do notexclude polymorphic variants, interspecies homologs, and alleles of theinvention.

The following eight groups each contain amino acids that areconservative substitutions for one another: 1) Alanine (A), Glycine (G);2) Aspartic acid (D), Glutamic acid (E); 3) Asparagine (N), Glutamine(Q); 4) Arginine (R), Lysine (K); 5) Isoleucine (I), Leucine (L),Methionine (M), Valine (V); 6) Phenylalanine (F), Tyrosine (Y),Tryptophan (W); 7) Serine (S), Threonine (T); and 8) Cysteine (C),Methionine (M) (see, e.g., Creighton, Proteins (1984)).

“Nucleic acid” or “polynucleotide” refers to deoxyribonucleotides orribonucleotides and polymers thereof in either single- ordouble-stranded form. The term encompasses nucleic acids containingknown nucleotide analogs or modified backbone residues or linkages,which are synthetic, naturally occurring, and non-naturally occurring,which have similar binding properties as the reference nucleic acid, andwhich are metabolized in a manner similar to the reference nucleotides.Examples of such analogs include, without limitation, phosphorothioates,phosphoramidates, methyl phosphonates, chiral-methyl phosphonates,2-O-methyl ribonucleotides, peptide-nucleic acids (PNAs).

Unless otherwise indicated, a particular nucleic acid sequence alsoimplicitly encompasses conservatively modified variants thereof (e.g.,degenerate codon substitutions) and complementary sequences, as well asthe sequence explicitly indicated. Specifically, degenerate codonsubstitutions may be achieved by generating sequences in which the thirdposition of one or more selected (or all) codons is substituted withmixed-base and/or deoxyinosine residues (Batzer et al., Nucleic AcidRes. 19:5081 (1991); Ohtsuka et al., J. Biol. Chem. 260:2605-2608(1985); Rossolini et al., Mol. Cell. Probes 8:91-98 (1994)). The termnucleic acid is used interchangeably with gene, cDNA, mRNA,oligonucleotide, and polynucleotide.

Polynucleotides may comprise a native sequence (i.e., an endogenoussequence that encodes an individual antigen or a portion thereof) of aprotein of interest or may comprise a variant of such a sequence as setforth above. Polynucleotide variants may contain one or moresubstitutions, additions, deletions and/or insertions such that thebiological activity of the encoded chimeric protein is not diminished,relative to a chimeric protein comprising native antigens. Variantspreferably exhibit at least about 70% identity, more preferably at leastabout 80% identity and most preferably at least about 90%, 95%, 96%,97%, 98% or 99% identity to a polynucleotide sequence that encodes anative polypeptide or a portion thereof.

Unless otherwise indicated, a particular nucleic acid sequence alsoimplicitly encompasses conservatively modified variants thereof (e.g.,degenerate codon substitutions) and complementary sequences, as well asthe sequence explicitly indicated. Specifically, degenerate codonsubstitutions may be achieved by generating sequences in which the thirdposition of one or more selected (or all) codons is substituted withmixed-base and/or deoxyinosine residues (Batzer et al., Nucleic AcidRes. 19:5081 (1991); Ohtsuka et al., J. Biol. Chem. 260:2605-2608(1985); Rossolini et al., Mol. Cell. Probes 8:91-98 (1994)). The termnucleic acid is used interchangeably with gene, cDNA, mRNA,oligonucleotide, and polynucleotide.

An “expression cassette” refers to a polynucleotide molecule comprisingexpression control sequences operatively linked to coding sequence(s).

A “vector” is a replicon in which another polynucleotide segment isattached, so as to bring about the replication and/or expression of theattached segment.

“Control sequence” or “control element” refers to polynucleotidesequences which are necessary to effect the expression of codingsequences to which they are ligated. The nature of such controlsequences differs depending upon the host organism; in prokaryotes, suchcontrol sequences generally include promoter, ribosomal binding site,and terminators; in eukaryotes, generally, such control sequencesinclude promoters, terminators and, in some instances, enhancers. Theterm “control sequences” is intended to include, at a minimum, allcomponents whose presence is necessary for expression, and may alsoinclude additional components whose presence is advantageous, forexample, leader sequences.

“Operably linked” refers to a juxtaposition wherein the components sodescribed are in a relationship permitting them to function in theirintended manner. A control sequence “operably linked” to a codingsequence is ligated in such a way that expression of the coding sequenceis achieved under conditions compatible with the control sequences.

Nucleic acid is “operably linked” when it is placed into a functionalrelationship with another nucleic acid sequence. For example, DNA for apresequence or secretory leader is operably linked to DNA for apolypeptide if it is expressed as a preprotein that participates in thesecretion of the polypeptide; a promoter or enhancer is operably linkedto a coding sequence if it affects the transcription of the sequence; ora ribosome binding site is operably linked to a coding sequence if it ispositioned so as to facilitate translation. Generally, “operably linked”means that the DNA sequences being linked are near each other, and, inthe case of a secretory leader, contiguous and in reading phase.However, enhancers do not have to be contiguous. Linking is accomplishedby ligation at convenient restriction sites. If such sites do not exist,the synthetic oligonucleotide adaptors or linkers are used in accordancewith conventional practice.

“Conservatively modified variants” also applies to nucleic acidsequences. With respect to particular nucleic acid sequences,conservatively modified variants refers to those nucleic acids whichencode identical or essentially identical amino acid sequences, or wherethe nucleic acid does not encode an amino acid sequence, to essentiallyidentical sequences. Because of the degeneracy of the genetic code, alarge number of functionally identical nucleic acids encode any givenprotein. For instance, the codons GCA, GCC, GCG and GCU all encode theamino acid alanine. Thus, at every position where an alanine isspecified by a codon, the codon can be altered to any of thecorresponding codons described without altering the encoded polypeptide.Such nucleic acid variations are “silent variations,” which are onespecies of conservatively modified variations. Every nucleic acidsequence herein which encodes a polypeptide also describes everypossible silent variation of the nucleic acid. One of skill willrecognize that each codon in a nucleic acid (except AUG, which isordinarily the only codon for methionine, and TGG, which is ordinarilythe only codon for tryptophan) can be modified to yield a functionallyidentical molecule. Accordingly, each silent variation of a nucleic acidwhich encodes a polypeptide is implicit in each described sequence withrespect to the expression product, but not with respect to actual probesequences.

The terms “identical” or percent “identity,” in the context of two ormore nucleic acids or polypeptide sequences, including siRNA andpolypeptides, refer to two or more sequences or subsequences that arethe same or have a specified percentage of amino acid residues ornucleotides that are the same (i.e., about 60% identity, preferably 65%,70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, orhigher identity over a specified region, when compared and aligned formaximum correspondence over a comparison window or designated region) asmeasured using a BLAST or BLAST 2.0 sequence comparison algorithms withdefault parameters described below, or by manual alignment and visualinspection (see, e.g., NCBI web site http://www.ncbi.nlm.nih.gov/BLAST/or the like). Such sequences are then said to be “substantiallyidentical.” This definition also refers to, or may be applied to, thecompliment of a test sequence. The definition also includes sequencesthat have deletions and/or additions, as well as those that havesubstitutions. As described below, the preferred algorithms can accountfor gaps and the like. Preferably, identity exists over a region that isat least about 25 amino acids or nucleotides in length, or morepreferably over a region that is 50-100 amino acids or nucleotides inlength.

For sequence comparison, typically one sequence acts as a referencesequence, to which test sequences are compared. When using a sequencecomparison algorithm, test and reference sequences are entered into acomputer, subsequence coordinates are designated, if necessary, andsequence algorithm program parameters are designated. Preferably,default program parameters can be used, or alternative parameters can bedesignated. The sequence comparison algorithm then calculates thepercent sequence identities for the test sequences relative to thereference sequence, based on the program parameters.

A “comparison window,” as used herein, includes reference to a segmentof any one of the number of contiguous positions selected from the groupconsisting of from 20 to the full length of the reference sequence,usually about 25 to 100, or 50 to about 150, more usually about 100 toabout 150 in which a sequence may be compared to a reference sequence ofthe same number of contiguous positions after the two sequences areoptimally aligned. Methods of alignment of sequences for comparison arewell-known in the art. Optimal alignment of sequences for comparison canbe conducted, e.g., by the local homology algorithm of Smith & Waterman,Adv. Appl. Math. 2:482 (1981), by the homology alignment algorithm ofNeedleman & Wunsch, J. Mol. Biol. 48:443 (1970), by the search forsimilarity method of Pearson & Lipman, Proc. Nat'l. Acad. Sci. USA85:2444 (1988), by computerized implementations of these algorithms(GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics SoftwarePackage, Genetics Computer Group, 575 Science Dr., Madison, Wis.), or bymanual alignment and visual inspection (see, e.g., Ausubel et al.,Current Protocols in Molecular Biology (eds. 1995 supplement)).

A preferred example of algorithm that is suitable for determiningpercent sequence identity and sequence similarity are the BLAST andBLAST 2.0 algorithms, which are described in Altschul et al., Nuc. AcidsRes. 25:3389-3402 (1977) and Altschul et al., J. Mol. Biol. 215:403-410(1990), respectively. BLAST and BLAST 2.0 are used, with the parametersdescribed herein, to determine percent sequence identity for the nucleicacids and proteins of the invention. Software for performing BLASTanalyses is publicly available through the National Center forBiotechnology Information (http://www.ncbi.nlm.nih.gov/). This algorithminvolves first identifying high scoring sequence pairs (HSPs) byidentifying short words of length W in the query sequence, which eithermatch or satisfy some positive-valued threshold score T when alignedwith a word of the same length in a database sequence. T is referred toas the neighborhood word score threshold (Altschul et al., supra). Theseinitial neighborhood word hits act as seeds for initiating searches tofind longer HSPs containing them. The word hits are extended in bothdirections along each sequence for as far as the cumulative alignmentscore can be increased. Cumulative scores are calculated using, fornucleotide sequences, the parameters M (reward score for a pair ofmatching residues; always >0) and N (penalty score for mismatchingresidues; always <0). For amino acid sequences, a scoring matrix is usedto calculate the cumulative score. Extension of the word hits in eachdirection are halted when: the cumulative alignment score falls off bythe quantity X from its maximum achieved value; the cumulative scoregoes to zero or below, due to the accumulation of one or morenegative-scoring residue alignments; or the end of either sequence isreached. The BLAST algorithm parameters W, T, and X determine thesensitivity and speed of the alignment. The BLASTN program (fornucleotide sequences) uses as defaults a wordlength (W) of 11, anexpectation (E) of 10, M=5, N=−4 and a comparison of both strands. Foramino acid sequences, the BLASTP program uses as defaults a wordlengthof 3, and expectation (E) of 10, and the BLOSUM62 scoring matrix (seeHenikoff & Henikoff, Proc. Natl. Acad. Sci. USA 89:10915 (1989))alignments (B) of 50, expectation (E) of 10, M=5, N=−4, and a comparisonof both strands.

“Naturally-occurring” as applied to an object refers to the fact thatthe object can be found in nature. For example, a polypeptide orpolynucleotide sequence that is present in an organism (includingviruses) that can be isolated from a source in nature and which has notbeen intentionally modified by man in the laboratory isnaturally-occurring.

The phrase “stringent hybridization conditions” refers to conditionsunder which a probe will hybridize to its target subsequence, typicallyin a complex mixture of nucleic acids, but to no other sequences.Stringent conditions are sequence-dependent and will be different indifferent circumstances. Longer sequences hybridize specifically athigher temperatures. An extensive guide to the hybridization of nucleicacids is found in Tijssen, Techniques in Biochemistry and MolecularBiology—Hybridization with Nucleic Probes, “Overview of principles ofhybridization and the strategy of nucleic acid assays” (1993).Generally, stringent conditions are selected to be about 5-10° C. lowerthan the thermal melting point (T_(m)) for the specific sequence at adefined ionic strength pH. The T_(m) is the temperature (under definedionic strength, pH, and nucleic concentration) at which 50% of theprobes complementary to the target hybridize to the target sequence atequilibrium (as the target sequences are present in excess, at T_(m),50% of the probes are occupied at equilibrium). Stringent conditions mayalso be achieved with the addition of destabilizing agents such asformamide. For selective or specific hybridization, a positive signal isat least two times background, preferably 10 times backgroundhybridization. Exemplary stringent hybridization conditions can be asfollowing: 50% formamide, 5×SSC, and 1% SDS, incubating at 42° C., or,5×SSC, 1% SDS, incubating at 65° C., with wash in 0.2×SSC, and 0.1% SDSat 65° C.

Nucleic acids that do not hybridize to each other under stringentconditions are still substantially identical if the polypeptides whichthey encode are substantially identical. This occurs, for example, whena copy of a nucleic acid is created using the maximum codon degeneracypermitted by the genetic code. In such cases, the nucleic acidstypically hybridize under moderately stringent hybridization conditions.Exemplary “moderately stringent hybridization conditions” include ahybridization in a buffer of 40% formamide, 1 M NaCl, 1% SDS at 37° C.,and a wash in 1×SSC at 45° C. A positive hybridization is at least twicebackground. Those of ordinary skill will readily recognize thatalternative hybridization and wash conditions can be utilized to provideconditions of similar stringency. Additional guidelines for determininghybridization parameters are provided in numerous reference, e.g., andCurrent Protocols in Molecular Biology, ed. Ausubel, et al., John Wiley& Sons.

For PCR, a temperature of about 36° C. is typical for low stringencyamplification, although annealing temperatures may vary between about32° C. and 48° C. depending on primer length. For high stringency PCRamplification, a temperature of about 62° C. is typical, although highstringency annealing temperatures can range from about 50° C. to about65° C., depending on the primer length and specificity. Typical cycleconditions for both high and low stringency amplifications include adenaturation phase of 90° C.-95° C. for 30 sec-2 min., an annealingphase lasting 30 sec.-2 min., and an extension phase of about 72° C. for1-2 min. Protocols and guidelines for low and high stringencyamplification reactions are provided, e.g., in Innis et al., PCRProtocols, A Guide to Methods and Applications, Academic Press, Inc.N.Y. (1990)).

The term “heterologous” when used with reference to a protein or anucleic acid indicates that the protein or the nucleic acid comprisestwo or more sequences or subsequences which are not found in the samerelationship to each other in nature. For instance, the nucleic acid istypically recombinantly produced, having two or more sequences fromunrelated genes arranged to make a new functional nucleic acid. Forexample, in one embodiment, the nucleic acid has a promoter from onegene arranged to direct the expression of a coding sequence from adifferent gene. Thus, with reference to the coding sequence, thepromoter is heterologous. Similarly, a heterologous protein indicatesthat the protein comprises two or more subsequences that are not foundin the same relationship to each other in nature (e.g., a fusionprotein). “Heterologous” accordingly includes those proteins andpolynucleotide sequences which are not found in a cell in which they areintroduced. Such proteins can be of mammalian, primate, human,reptilian, or insect origin.

The term “recombinant” when used with reference, e.g., to a cell, ornucleic acid, protein, or vector, indicates that the cell, nucleic acid,protein or vector, has been modified by the introduction of aheterologous nucleic acid or protein or the alteration of a nativenucleic acid or protein, or that the cell is derived from a cell somodified. Thus, for example, recombinant cells express genes that arenot found within the native (non-recombinant) form of the cell orexpress native genes that are otherwise abnormally expressed,under-expressed or not expressed at all. Methods of making recombinantcells using vectors, promoters, and other gene regulatory agents, andnucleic acids encoding heterologous proteins of interest are well knownto persons of ordinary skill in the art.

The term “isolated” with regard to polypeptide or peptide fragment orpolynucleotides as used herein refers to a polypeptide or a peptidefragment or polynucleotide which either has no naturally-occurringcounterpart or has been separated or purified from components whichnaturally accompany it, e.g., in normal tissues such as lung, kidney, orplacenta, tumor tissue such as colon cancer tissue, or body fluids suchas blood, serum, or urine. Typically, the polypeptide or peptidefragment or polynucleotide is considered “isolated” when it is at least70%, by dry weight, free from the proteins and other naturally-occurringorganic molecules with which it is naturally associated. Preferably, apreparation of a polypeptide (or peptide fragment thereof) orpolynucleotide of the invention is at least 80%, more preferably atleast 90% or 95%, and most preferably at least 99%, by dry weight, thepolypeptide (or the peptide fragment thereof), or polynucleotide,respectively, of the invention. Thus, for example, a preparation ofpolypeptide x is at least 80%, more preferably at least 90%, and mostpreferably at least 99%, by dry weight, polypeptide x. Since apolypeptide or polynucleotide that is chemically synthesized is, by itsnature, separated from the components that naturally accompany it, thesynthetic polypeptide is “isolated.”

Once a recombinant chimeric protein is expressed, it can be identifiedby assays based on the physical or functional properties of the product,including radioactive labeling of the product followed by analysis bygel electrophoresis, radioimmunoassay, ELISA, bioassays, etc.

In some embodiments, the mitogenic stimulus or agent conferring a growthdisadvantage can be an antibody. Antibodies can also be used to detector target ex vivo cells engrafted in the host. The targeting can be forthe purpose of killing a cell which has proved harmful. “Antibody”refers to a polypeptide comprising a framework region from animmunoglobulin gene or fragments thereof that specifically binds andrecognizes an antigen. The recognized immunoglobulin genes include thekappa, lambda, alpha, gamma, delta, epsilon, and mu constant regiongenes, as well as the myriad immunoglobulin variable region genes. Lightchains are classified as either kappa or lambda. Heavy chains areclassified as gamma, mu, alpha, delta, or epsilon, which in turn definethe immunoglobulin classes, IgG, IgM, IgA, IgD and IgE, respectively.Typically, the antigen-binding region of an antibody will be mostcritical in specificity and affinity of binding.

An exemplary immunoglobulin (antibody) structural unit comprises atetramer. Each tetramer is composed of two identical pairs ofpolypeptide chains, each pair having one “light” (about 25 kD) and one“heavy” chain (about 50-70 kD). The N-terminus of each chain defines avariable region of about 100 to 110 or more amino acids primarilyresponsible for antigen recognition. The terms variable light chain(V_(L)) and variable heavy chain (V_(H)) refer to these light and heavychains respectively.

Antibodies exist, e.g., as intact immunoglobulins or as a number ofwell-characterized fragments produced by digestion with variouspeptidases. Thus, for example, pepsin digests an antibody below thedisulfide linkages in the hinge region to produce F(ab)′₂, a dimer ofFab which itself is a light chain joined to V_(H)-C_(H)1 by a disulfidebond. The F(ab)′₂ may be reduced under mild conditions to break thedisulfide linkage in the hinge region, thereby converting the F(ab)′₂dimer into an Fab′ monomer. The Fab′ monomer is essentially Fab withpart of the hinge region (see Fundamental Immunology (Paul ed., 3d ed.1993)). While various antibody fragments are defined in terms of thedigestion of an intact antibody, one of skill will appreciate that suchfragments may be synthesized de novo either chemically or by usingrecombinant DNA methodology. Thus, the term antibody, as used herein,also includes antibody fragments either produced by the modification ofwhole antibodies, or those synthesized de novo using recombinant DNAmethodologies (e.g., single chain Fv) or those identified using phagedisplay libraries (see, e.g., McCafferty et al., Nature, 348:552-554(1990)).

For preparation of antibodies, e.g., recombinant, monoclonal, orpolyclonal antibodies, many technique known in the art can be used (see,e.g., Kohler & Milstein, Nature, 256:495-497 (1975); Kozbor et al.,Immunology Today, 4:72 (1983); Cole et al., pp. 77-96 in MonoclonalAntibodies and Cancer Therapy, Alan R. Liss, Inc. (1985); Coligan,Current Protocols in Immunology (1991); Harlow & Lane, Antibodies, ALaboratory Manual (1988); and Goding, Monoclonal Antibodies: Principlesand Practice (2d ed. 1986)). The genes encoding the heavy and lightchains of an antibody of interest can be cloned from a cell, e.g., thegenes encoding a monoclonal antibody can be cloned from a hybridoma andused to produce a recombinant monoclonal antibody. Gene librariesencoding heavy and light chains of monoclonal antibodies can also bemade from hybridoma or plasma cells. Random combinations of the heavyand light chain gene products generate a large pool of antibodies withdifferent antigenic specificity (see, e.g., Kuby, Immunology (3^(rd) ed.1997)). Techniques for the production of single chain antibodies orrecombinant antibodies (U.S. Pat. No. 4,946,778, U.S. Pat. No.4,816,567) can be adapted to produce antibodies to polypeptides of thisinvention. Also, transgenic mice, or other organisms such as othermammals, may be used to express humanized or human antibodies (see,e.g.,U U.S. Pat. Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126;5,633,425; 5,661,016, Marks et al., Bio/Technology, 10:779-783 (1992);Lonberg et al., Nature, 368:856-859 (1994); Morrison, Nature, 368:812-13(1994); Fishwild et al., Nature Biotechnology, 14:845-51 (1996);Neuberger, Nature Biotechnology, 14:826 (1996); and Lonberg & Huszar,Intern. Rev. Immunol., 13:65-93 (1995)). Alternatively, phage displaytechnology can be used to identify antibodies and heteromeric Fabfragments that specifically bind to selected antigens (see, e.g.,McCafferty et al., Nature, 348:552-554 (1990); Marks et al.,Biotechnology, 10:779-783 (1992)). Antibodies can also be madebispecific, i.e., able to recognize two different antigens (see, e.g.,WO 93/08829, Traunecker et al., EMBO J., 10:3655-3659 (1991); and Sureshet al., Methods in Enzymology, 121:210 (1986)). Antibodies can also beheteroconjugates, e.g., two covalently joined antibodies, orimmunotoxins (see, e.g., U.S. Pat. No. 4,676,980 , WO 91/00360; WO92/200373; and EP 03089).

Methods for humanizing or primatizing non-human antibodies are wellknown in the art. Generally, a humanized antibody has one or more aminoacid residues introduced into it from a source which is non-human. Thesenon-human amino acid residues are often referred to as import residues,which are typically taken from an import variable domain. Humanizationcan be essentially performed following the method of Winter andco-workers (see, e.g., Jones et al., Nature, 321:522-525 (1986);Riechmann et al., Nature, 332:323-327 (1988); Verhoeyen et al., Science,239:1534-1536 (1988) and Presta, Curr. Op. Struct. Biol., 2:593-596(1992)), by substituting rodent CDRs or CDR sequences for thecorresponding sequences of a human antibody. Accordingly, such humanizedantibodies are chimeric antibodies (U.S. Pat. No. 4,816,567), whereinsubstantially less than an intact human variable domain has beensubstituted by the corresponding sequence from a non-human species. Inpractice, humanized antibodies are typically human antibodies in whichsome CDR residues and possibly some FR residues are substituted byresidues from analogous sites in rodent antibodies.

A “chimeric antibody” is an antibody molecule in which (a) the constantregion, or a portion thereof, is altered, replaced or exchanged so thatthe antigen binding site (variable region) is linked to a constantregion of a different or altered class, effector function and/orspecies, or an entirely different molecule which confers new propertiesto the chimeric antibody, e.g., an enzyme, toxin, hormone, growthfactor, drug, etc.; or (b) the variable region, or a portion thereof, isaltered, replaced or exchanged with a variable region having a differentor altered antigen specificity.

In one embodiment, the antibody is conjugated to an “effector” moiety.The effector moiety can be any number of molecules, including labelingmoieties such as radioactive labels or fluorescent labels, or can be atherapeutic moiety. In one aspect the antibody modulates the activity ofthe protein.

The phrase “specifically (or selectively) binds” to an antibody or“specifically (or selectively) immunoreactive with,” when referring to aprotein or peptide, refers to a binding reaction that is determinativeof the presence of the protein, often in a heterogeneous population ofproteins and other biologics. Thus, under designated immunoassayconditions, the specified antibodies bind to a particular protein atleast two times the background and more typically more than 10 to 100times background. Specific binding to an antibody under such conditionsrequires an antibody that is selected for its specificity for aparticular protein. For example, polyclonal antibodies can be selectedto obtain only those polyclonal antibodies that are specificallyimmunoreactive with the selected antigen and not with other proteins.This selection may be achieved by subtracting out antibodies thatcross-react with other molecules. A variety of immunoassay formats maybe used to select antibodies specifically immunoreactive with aparticular protein. For example, solid-phase ELISA immunoassays areroutinely used to select antibodies specifically immunoreactive with aprotein (see, e.g., Harlow & Lane, Antibodies, A Laboratory Manual(1988) for a description of immunoassay formats and conditions that canbe used to determine specific immunoreactivity).

Methods of Conferring a Growth Disadvantage

Irradiation can be used to confer a growth disadvantage on endogenouscells of the target organ. For instance, toward the development of aclinically applicable approach to liver repopulation, we have exploredpreparative hepatic irradiation (HIR) to injure host hepatocytes andprevent them from proliferating and competing with donor hepatocytes inresponse to mitotic stimuli. Preparative irradiation is routinely usedfor bone marrow transplantation (Thomas, E. et al., N Engl J Med,292:832-843 (1975)), but we were the first to use HIR to facilitate HTin rodent models (Guha, C. et al., Int J Radiat Oncol Biol Phys,49:451-457 (2001); Guha, C. et al., Artif Organs, 25:522-528 (2001);Guha, C. et al., Hepatology, 36:354-362 (2002); Takahashi, M. et al.,Gene Ther, 10:304-313 (2003); Guha, C. et al., Cancer Res, 59:5871-5874(1999)). Ionizing radiation (IR) induces apoptosis of bone marrow cellsand thereby, makes “room” for donor cell engraftment. Our resultsdemonstrate that HIR in combination with a compensatory hepaticregenerative stimuli, such as, partial hepatectomy (PH) (Guha, C. etal., Hepatology, 36:354-362 (2002); Guha, C. et al., Cancer Res,59:5871-5874 (1999)), Fas-induced apoptosis (Takahashi, M. et al., GeneTher, 10:304-313 (2003)), or portal vein branch ligation (Deb, N. etal., Hepatology, 34 (4):153A., 34:153A (2001)), or a direct mitoticstimuli, provided by hepatotropic growth factors, such as, thyroidhormone (Parashar, B. et al., Hepatology, 32:206A (2000)), or hepatocytegrowth factor (HGF) (Guha, C. et al., Am J Nephrol, 25:161-170 (2005))induces extensive repopulation of transplanted hepatocytes in the hostliver. We have demonstrated that HIR, in combination with proliferativestimuli for hepatocytes, could potentially suppress host hepatocellularproliferation and induce post-mitotic death, thus making “room” fordonor hepatocytes that preferentially proliferate and repopulate theirradiated host liver. HIR can be safely administered in the clinicusing stereotactic radiosurgery (SRS) or 3-D conformal RT (3-D CRT)techniques and can be used as a preparative regimen for HT. Thus,preparative HIR can facilitate HT for i) the treatment of inheritedliver diseases, ii) ex vivo hepatic gene therapy, iii) rescuing patientswith liver cancer, following chemotherapy or radiation therapy, or otherliver damage; and iv) expanding human hepatocytes in animal liver forgenerating animal models for human-specific infections (Table 1).

First, although PH provided the mitotic signal in our initialrepopulation experiments, a non-invasive substitute to PH is moredesirable for clinical application. Accordingly, we have examinedwhether HIR in combination with hepatic growth factors, such as, HGF andEGF, could promote repopulation of transplanted hepatocytes. Use of anactivating antibody to the HGF receptor, c-met, to promote selectiveproliferation of hepatocytes in the irradiated liver is alsocontemplated. Second, radiation-induced liver injury is a function ofmean liver dose and the irradiated liver volume (Lawrence, T. et al.,International Journal of Radiation Oncology, Biology, Physics,19:1041-1047 (1990); Dawson, L. et al., Int J Radiat Oncol Biol Phys,53:810-821 (2002)) in humans. A lower dose of HIR, or partial liverirradiation is desirable for clinical application of HIR. Partial liverirradiation is well tolerated in cancer patients and with moderntechniques of IMRT, doses higher than 50 Gy to parts of the liver cansafely be offered to patients in the clinic. Our initial studiesdemonstrate that HIR administered to the anterior lobes of the liver caninduce selective lobar repopulation of donor cells (Deb, N. et al.,Hepatology, 34 (4):153A., 34:153A (2001)). It is accordinglycontemplated that partial liver irradiation along with hepatic growthfactors can be used in preparative regimens of HT.

TABLE 1 The scope of liver cell transplantation and hepatocyte-basedgene therapy A. REPLACEMENT OF A MISSING GENE PRODUCT Liver manifestsdisease Extrahepatic organs manifest disease Genetic Disorders Metabolicdeficiency disorders   Wilson's disease   Crigler-Najjar Syndrome  Lipidoses, e.g., Niemann-Pick disease   Familial hypercholesterolemia  Tyrosinemia Type I   Defects in carbohydrate metabolism  Protoporphyria Coagulation Disorders   Ornithine transcarbamylase  Hemophilia A & Factor IX deficiency   deficiency B. MASSIVEREPLACEMENT OF HOST   Primary hyperoxaluria HEPATOCYTES THAT EXPRESS AN  α-1 antitrypsin deficiency (mutant OFFENDING GENE   A1AT) C. REPLACEDISEASED HEPATOCYTES:   Acute liver failure   AMELIORATION OFRT/DRUG-INDUCED   Chronic viral hepatitis and cirrhosis   LIVER INJURY  Drug or Radiation-induced liver   “BRIDGE” TO OLT IN LIVER FAILURE  injury in cancer patients   PATIENTS D. EXPRESSION OF GENES THAT AREE. DEVELOPMENT OF HUMAN-MOUSE NORMALLY NOT EXPRESSED IN THE LIVER LIVERCHIMERA/ Hormones, e.g., insulin, immunosuppressive GENERATION OF ANIMALMODELS OF  Genes, anti-angiogenic agents, cytokine HUMAN-SPECIFICINFECTIONS  immunomodulation   Malaria   (for suppressing tumor growth)  Viral Hepatitis

Additionally, the invention provides methods of pretreating an organ toreduce the growth or proliferation of endogenous cells of the organ byadministering an agent selectively or predominantly toxic to theendogenous cells of the organ as opposed to other organs. The toxiceffects and target organs for a variety of chemicals are disclosed inRegistry of Toxic Effects of Chemical Substances (RTECS), RTECS (NIOSH1980 or later editions, including 1995). RTECS is a database of toxicityinformation compiled from the published scientific literature. Prior to2001, RTECS was maintained by US National Institute for OccupationalSafety and Health (NIOSH). Now, it is maintained by Elsevier MDL. See,also, Olson et al. Ed., Poisoning and Drug Overdose, 5th Edition,published by McGraw Hill/Lange for a listing of toxic agents and theireffects and target organs. For instance, as to the liver, somehalogenated compounds and carcinogens which are selectively orprincipally toxic for the liver may be used.

Methods of Engrafting and Repopulating Ex Vivo Cell Isolation.

Cells can be isolated with a modified collagenase perfusion method froma mammalian organ or tissue, as originally described by Berry and Friend(Takahashi, M. et al., Gene Ther, 10:304-313 (2003)). Afterdissociation, cells can be filtered through a Dacron mesh of a dimensioncorresponding to the cell of interest and then washed twice at 50×g for1 min each. Cell viability can be determined by trypan blue dyeexclusion. Cells with >90% viability can be used for transplantation. Exvivo cells can be adult somatic cells, adult progenitor cells, adultstem cells, embryonic progenitor cells, or embryonic stem cells. Sourcesof such cells are well known to persons of ordinary skill in the art.For example, with regard to the liver, hepatocytes can be isolated witha modified collagenase perfusion method using male F344 rats, asoriginally described by Berry and Friend (Takahashi, M. et al., GeneTher, 10:304-313 (2003)). After liver dissociation, cells were filteredthrough an 80-μm Dacron mesh and washed twice at 50×g for 1 min each.Cell viability can be determined by trypan blue dye exclusion.Hepatocytes with >90% viability were used for transplantation (see,also, Guha, C. et al., Cancer Research 59, 5871-5874, (1999) and, also,Nowak, G., et al., Gut 54:972-979 (2005)).

Administration of Ex Vivo Cells

Ex vivo cells are introduced into the subject in a number which dependsupon the species and organ to be engrafted and the extent of the needfor such therapy. Ex vivo cells can be injected directly into thespleen, kidney capsule, or target organ of the subject as describedpreviously (Guha, C. et al., Artif Organs, 25:522-528 (2001)) oradministered intraperitoneally or other site of engraftment. They mayalso be administered intravenously or intraportally (in the case of theliver). For instance, when administering hepatocytes to the rat, underether anesthesia, the spleen can be exposed, and 5×10⁶ hepatocytessuspended in 0.5 ml of RPMI 1640 can be injected into the splenic pulp.Generally, hepatocytes can be administered in suitable media providingsingle or divided doses of from 1×10⁵ to 5×10⁹ cells per treatment.Total dosages, administered singly or as a divided dose, may be from 1from 1×10⁵ to 5×10¹⁰ ex vivo cells/kg of body weight; in someembodiments the total dosages, administered singly or as a divided dose,may be from 1 from 1×10⁶ to 1×10⁹ ex vivo cells/kg of body weight; insome embodiments the total dosages, administered singly or as a divideddose, may be from 1 from 1×10⁷to 5×10⁸ex vivo cells/kg of body weight.

Methods of Determining Engraftment Histological Analysis.

By methods known to one of ordinary skill in the art, engrafted ex vivocells can be distinguished from endogenous cells by the use of antigenicmarkers, identifying chromosomal or genomic nucleic acid sequencedifferences between the engrafted and endogenous cells, fluorescentmarkers such as GFP, or enzymatic markers such as DPPIV, or according toa functional enzyme present in the ex vivo cell and deficient in thehost endogenous cells. Sections of an organ can be embedded in OCT,frozen in liquid nitrogen, and stored at −70° C. or fixed in formalinfor paraffin embedding and standard H&E staining. For the liver,Reticulin and trichrome stains can be performed in a standardhistopathology laboratory. Ex vivo cells can be distinguished fromendogenous cells by the use of antigenic markers, identifyingchromosomal or genomic nucleic acid sequence differences between theengrafted and endogenous cells, fluorescent markers such as GFP, orenzymatic markrs such as DPPIV, or according to a functional enzymepresent in the ex vivo cell and deficient in the host endogenous cells.For instance, in the case of DPPIV marked ex vivo cells, DPPIV activityin situ can be assessed using 5-μm-thick cryostat sections fixed inchloroform and acetone (1:1, v/v) for 10 min at 40° C., as describedpreviously (Guha, C. et al., Cancer Res, 59:5871-5874 (1999)) . Afterair drying, sections can be incubated for 30 min at room temperature ina solution containing 0.4 mg glycyl-L-proline-4-methoxy-2-naphthylamide,along with 1 mg Fast Blue B salt in PBS (pH 7.4) and the fluorescentreaction products detected. The reaction can be terminated by washingwith water and sections and counterstaining with hematoxylin.

A variety of model systems can be used to detect engraftment andrepopulation of donor hepatocytes. For instance, one can use a mousemodel, where transgenic beta-galactosidase (B-gal)-expressing (Rosa)C57B1/6 hepatocytes are transplanted into wild-type C57B1/6 mice. Or,DPPIV+ve F344 hepatocytes can be transplanted into congeneic, DPPIV−veF344 host liver. Since DPPIV is highly expressed in the bile canaliculardomain of the hepatocytes, the transplanted cells can easily be detectedby enzyme histochemistry. In addition, after characterizing anoninvasive, robust, preparative regimen of hepatocyte repopulation, onecan further examine its effectiveness in ameliorating a rodent model ofmetabolic liver disease, such as the Gunn rat, which is a model forCrigler-Najjar syndrome. Experiments can be simultaneously performed inmore than one species. Initial dose of HIR would be 50 Gy, which hasbeen very effective in inducing donor cell proliferation in our studiesand is safe in rodents. One can perform a dose response study of HIR(e.g., 10, 20, 30 and 50 Gy), in order to identify the lowest dose ofHIR that permits effective donor cell repopulation. To investigate thenature of radiation injury to the host hepatocytes, experiments can alsobe performed with mice that received HIR and HGF without HT. Animalsfrom various cohorts can be sacrificed at various time points (1d, 2d,3d, 1 wk, 3 wk, 6 wk and 12 wk) and liver sections can be stained withH&E for histopathological analysis. BrdU and TUNEL staining can beperformed for examining hepatocyte proliferation and apoptosis,respectively.

Organ Function Tests

In the clinical setting, engraftment can be assessed by biopsy withanalyses as described above. Additionally, clinical tests can be used toassess the extent to which homeostasis is supported by the engraftedorgan. Improvement in one or more clinical parameters related to thefunctioning of a target or engrafted organ can be used to indirectlyassess the efficacy of the engraftment. Suitable clinical tests willvary with respect to the organ. With regard to the liver, standard liverfunction tests which monitor blood levels of any of alanineaminotransferase; spartate aminotransferase; alkaline phosphatase;gamma-glutamyltransferase, bilirubin, or ammonia may be used.

i) Donor hepatocyte engraftment and repopulation. Donor cells can beidentified by beta-galactosidase and DPP IV histochemistry in C57B1/6mice and DPP IV−ve, F344 rats, respectively. To demonstrate theengraftment of transplanted cells, double staining forbeta-galactosidase and ATPase in the rosa/B16 model or for DPPIV andATPase in the DPP IV−ve can be performed in the F344 model. Donor cellproliferation in DPPIV−ve rats can be determined by co-localization ofDPPIV activity (histochemistry) and immunostaining for BrdUincorporation in the nuclei, according to previously published methods(Gupta, S. et al., Proceedings of the National Academy of Sciences ofthe United States of America, 92:5860-5864 (1995)).

ii) Physiological function of repopulated hepatocytes. The ability oftransplanted cells to perform unique hepatocyte biochemical functions,albumin synthesis (albumin immunostaining), glucose metabolism (stainfor glucose-6-phosphatase) and gluconeogenesis (glycogen staining) canbe examined in fresh frozen section according to published protocols(Laconi, E. et al., Am J Pathol, 153:319-329 (1998)). In Gunn rats,amelioration of hyperbilirubinemia can be used to indicate the degree ofrepopulation and the physiological function of the transplantedhepatocytes. At various time points (1, 2, 3 and 6 months), animals canbe sacrificed and the function of the engrafted normal hepatocytes canbe evaluated by measuring UGT1A1 activity in liver biopsy specimens,performing immunoblot analysis of UGT1A1 and immunohistochemistry todetect donor UGT1A1+ve hepatocytes and by determining the excretion ofbilirubin glucuronides in bile.

iii) Toxicities of the preparative regimens. As described in ourpublications (Guha, C. et al., Hepatology, 36:354-362 (2002); Guha, C.et al., Cancer Res, 59:5871-5874 (1999); Nakatani, T. et al., J BiolChem, 277:9562-9569 (2002)), serum albumin, transferrin, AST, ALT, GGT,GST-pi and alpha-feto protein (AFP) can be measured to examine thenormal physiological functions of the repopulated hepatocytes and todetermine any potential manifestations of radiation injury andtumorigenesis at the end of experiments. H & E staining of the liverbiopsies can be performed to examine for histopathological evidence ofhepatic radiation injury and tumorigenesis.

Gene Therapy

In some embodiments, the ex vivo cell to be engrafted is a recombinantcell transduced or transformed ex vivo to express a protein or to haveincreased ability to compete with endogenous cells upon engrafting or togrow in culture. In some embodiments, the protein may function as amarker, to provide a function deficient in the host organ or to modulatethe growth and/or survival of the ex vivo cell (e.g., may provide amitogenic stimuli to growth of the ex vivo cells). The nucleic acidexpressing the genome is operably linked to regulatory elements whichmay be introduced or transduced into the cell by conventional meanswhich are well known in the art. Construction of suitable vectorscontaining the desired gene coding and control sequences employsstandard ligation and restriction techniques, which are well understoodin the art (see Maniatis et al., in Molecular Cloning: A LaboratoryManual, Cold Spring Harbor Laboratory, N.Y. (1982)). Isolated plasmids,DNA sequences, or synthesized oligonucleotides are cleaved, tailored,and religated in the form desired. The regulatory elements may be inturn regulated by agents which are subject to manipulation in the host(e.g., heat shock promoters or

A variety of viral and non-viral delivery vectors useful to achieveexpression of nucleotide sequences in transduced cells are known in theart. See, e.g. Boulikas, T in Gene Therapy and Molecular Biology, Volume1 (Boulikas, T. Ed.) 1998 Gene Therapy Press, Palo Alto, Calif. pages1-172. Methods of non-viral delivery of nucleic acids includelipofection, microinjection, biolistics, virosomes, liposomes,immunoliposomes, polycation or lipid:nucleic acid conjugates, naked DNA,artificial virions, and agent-enhanced uptake of DNA. Lipofection isdescribed in, e.g., U.S. Pat. No. 5,049,386, U.S. Pat. No. 4,946,787;and U.S. Pat. No. 4,897,355) and lipofection reagents are soldcommercially (e.g., Transfectam™ and Lipofectin™). Cationic and neutrallipids that are suitable for efficient receptor-recognition lipofectionof polynucleotides include those of Felgner, WO 91/17424, WO 91/16024.Delivery can be to cells (ex vivo administration) or target tissues (invivo administration). A targeting construct for knocking the desiredfirst gene into another second gene having suitable expression can be areplacement vector designed to replace the second gene coding sequenceswith those of the first (see, Yin et al, Stem Cells 20:338-346 (2002).As indicated in the Examples, genes may also be modified using viralvectors as known in the art.

Examples of non-viral delivery systems used to introduce a gene to atarget cell include expression plasmids capable of directing theexpression of the protein. Expression plasmids are autonomouslyreplicating, extrachromosomal circular DNA molecules, distinct from thenormal genome and nonessential for cell survival under nonselectiveconditions capable of effecting the expression of a DNA sequence in thetarget cell. The expression plasmid may also contain promoter, enhanceror other sequences aiding expression of the therapeutic gene and/orsecretion can also be included in the expression vector. Additionalgenes, such as those encoding drug resistance, can be included to allowselection or screening for the presence of the recombinant vector. Suchadditional genes can include, for example, genes encoding neomycinresistance, multi-drug resistance, thymidine kinase, beta-galactosidase,dihydrofolate reductase (DHFR), and chloramphenicol acetyl transferase.

The expression plasmid containing the gene may be encapsulated inliposomes. Liposomes include emulsions, foams, micelles, insolublemonolayers, liquid crystals, phospholipid dispersions, lamellar layersand the like. The delivery of nucleic acids to cells using liposomecarriers is well known in the art. A variety of methods are availablefor preparing liposomes, as described in, e.g., Szoka et al. Ann. Rev.Biophys. Bioeng. 9:467 (1980), Szoka, et al. U.S. Pat. No 4,394,448issued Jul. 19, 1983, as well as U.S. Pat. Nos. 4,235,871, 4,501,728,4,837,028, and 5,019,369. Liposomes useful in the practice of thepresent invention may be formed from one or more standardvesicle-forming lipids, which generally include neutral and negativelycharged phospholipids and a sterol, such as cholesterol. Examples ofsuchvesicle forming lipids include DC-chol, DOGS, DOTMA, DOPE, DOSPA, DMRIE,DOPC, DOTAP, DOME, DMRIE-HP, n-spermidine cholesterol carbamate andother cationic lipids as disclosed in U.S. Pat. No. 5,650,096. Theselection of lipids is generally guided by consideration of, e.g.,liposome size, acid lability and stability of the liposomes in the bloodstream. Additional components may be added to the liposome formulationto increase serum half-life such as polyethylene glycol coating (socalled “PEG-ylation”) as described in U.S. Pat. No. 5,013,556 issued May7, 1991 and U.S. Pat. No. 5,213,804 issued May 25, 1993.

In order to provide directed delivery of the non-viral gene to aparticular cell, it may be advantageous to incorporate elements into thenon-viral delivery system which facilitate cellular targeting. Forexample, a lipid encapsulated expression plasmid may incorporatemodified surface cell receptor ligands to facilitate targeting.

In one embodiment of the invention as exemplified herein, the vector isa viral vector. The terms virus(es) and viral vector(s) are usedinterchangeably herein. The viruses useful in the practice of thepresent invention include recombinantly modified enveloped ornon-enveloped DNA and RNA viruses, preferably selected frombaculoviridiae, parvoviridiae, picornoviridiae, herpesveridiae,poxviridae, adenoviridiae, or picornnaviridiae. The viral genomes may bemodified by conventional recombinant DNA techniques to provideexpression of the gene and may be engineered to be replicationdeficient, conditionally replicating or replication competent. Chimericviral vectors which exploit advantageous elements of each of the parentvector properties (See e.g., Feng, et al. (1997) Nature Biotechnology,15:866-870) may also be useful in the practice of the present invention.Minimal vector systems in which the viral backbone contains only thesequences needed for packaging of the viral vector and may optionallyinclude a gene expression cassette may also be employed in the practiceof the present invention. In some instances it may be advantageous touse vectors derived from different species from that to be treated whichpossess favorable pathogenic features such as avoidance of pre-existingimmune response. For example, equine herpes virus vectors for human genetherapy are described in WO98/27216 published Aug. 5, 1998. The vectorsare described as useful for the treatment of humans as the equine virusis not pathogenic to humans. Similarly, ovine adenoviral vectors may beused in human gene therapy as they are claimed to avoid the antibodiesagainst the human adenoviral vectors. Such vectors are described in WO97/06826 published Apr. 10, 1997.

Many viruses exhibit the ability to infect a broad range of cell types.However, in some applications it may be desirable to infect only acertain subpopulation of cells. Consequently, a variety of techniqueshave evolved to facilitate selective or “targeted” vectors to result inpreferential infectivity of the mature viral particle of a particularcell type. Cell type specificity or cell type targeting may also beachieved in vectors derived from viruses having characteristically broadinfectivity such as adenovirus by the modification of the viral envelopeproteins. For example, cell targeting has been achieved with adenovirusvectors by selective modification of the viral genome knob and fibercoding sequences to achieve expression of modified knob and fiberdomains having specific interaction with unique cell surface receptors.

In one embodiment of the invention as exemplified herein, the vector isan adenoviral vector. The use of adenoviral vectors for the delivery ofexogenous transgenes are well known in the art. See e.g., Zhang, W-W.Cancer Gene Therapy, 6:113-138 (1999). Vectors can also be derived fromthe adenoviral, adeno-associated viral and retroviral genomes. In themost preferred practice of the invention, the vectors are derived fromthe human adenovirus genome. The replicative capacity of such vectorsmay be attenuated (to the point of being considered “replicationdeficient”) by modifications or deletions in the E1a and/or E1b codingregions.

The viral genome may be modified to include inducible promoters whichachieve replication or expression only under certain conditions.Examples of inducible promoters are known in the art (See, e.g. Yoshidaand Hamada, Biochem. Biophys. Res. Comm., 230:426-430 (1997); Iida, etal., J. Virol., 70(9):6054-6059 (1996); Hwang, et al., J. Virol,71(9):7128-7131 (1997); Lee, et al., Mol. Cell. Biol., 17(9):5097-5105(1997); and Dreher, et al., J. Biol. Chem., 272(46); 29364-29371 (1997).The viruses may also be designed to be selectively replicating virusessuch as those described in Ramachandra, et al. PCT InternationalPublication No. WO 00/22137, International Application No.PCT/US99/21452 published Apr. 20, 2000 and Howe, J., PCT InternationalPublication No. WO WO0022136, International Application No.PCT/US99/21451 published Apr. 20, 2000. The virus may also be modifiedto be attenuated for replication in certain cell types. For example theadenovirus dl1520 containing a specific deletion in the E1b55K gene(Barker and Berk (1987) Virology 156: 107) has been used withtherapeutic effect in human beings. Such vectors are also described inMcCormick (United States Patent No. 5,677,178 issued October 14, 1997)and McCormick, United States Patent No 5,846,945 issued December 8,1998.

Methods of Administration and Pharmaceutical Compositions of ActiveAgents

The pharmaceutically active agents, including but not limited topharmaceutical agents which disadvantage the endogenous cells withrespect to the engrafted ex vivo cells, the mitogenic compositions, andimmunosuppressive agents for use according to the invention can beadministered to a subject in accord with known methods, such asintravenous administration, e.g., as a bolus or by continuous infusionover a period of time, by intramuscular, intraperitoneal,intracerobrospinal, subcutaneous, intra-articular, intrasynovial,intrathecal, oral, topical, or inhalation routes. Intravenous orsubcutaneous administration of biopolymers is preferred. Theadministration may be local or systemic.

The compositions for administration will commonly comprise the activeagent as described herein dissolved in a pharmaceutically acceptablecarrier, preferably an aqueous carrier. A variety of aqueous carrierscan be used, e.g., buffered saline and the like. These solutions aresterile and generally free of undesirable matter. These compositions maybe sterilized by conventional, well known sterilization techniques. Thecompositions may contain pharmaceutically acceptable auxiliarysubstances as required to approximate physiological conditions such aspH adjusting and buffering agents, toxicity adjusting agents and thelike, for example, sodium acetate, sodium chloride, potassium chloride,calcium chloride, sodium lactate and the like. The concentration ofactive agent in these formulations can vary widely, and will be selectedprimarily based on fluid volumes, viscosities, body weight and the likein accordance with the particular mode of administration selected andthe patient's needs.

Thus, a typical pharmaceutical composition for intravenousadministration will vary according to the active agent. Actual methodsfor preparing parenterally administrable compositions will be known orapparent to those skilled in the art and are described in more detail insuch publications as Remington: The Science and Practice of Pharmacy,20th ed., Lippincott, Williams, and Wilkins, (2000).

The pharmaceutical compositions can be administered in a variety of unitdosage forms depending upon the method of administration. For example,unit dosage forms suitable for oral administration include, but are notlimited to, powder, tablets, pills, capsules and lozenges. It isrecognized that antibodies when administered orally, should be protectedfrom digestion. This is typically accomplished either by complexing themolecules with a composition to render them resistant to acidic andenzymatic hydrolysis, or by packaging the molecules in an appropriatelyresistant carrier, such as a liposome or a protection barrier. Means ofprotecting agents from digestion are well known in the art.

Pharmaceutical formulations can be prepared by mixing an active agenthaving the desired degree of purity with optional pharmaceuticallyacceptable carriers, excipients or stabilizers. Such formulations can belyophilized formulations or aqueous solutions. Acceptable carriers,excipients, or stabilizers are nontoxic to recipients at the dosages andconcentrations used. Acceptable carriers, excipients or stabilizers canbe acetate, phosphate, citrate, and other organic acids; antioxidants(e.g., ascorbic acid) preservatives low molecular weight polypeptides;proteins, such as serum albumin or gelatin, or hydrophilic polymers suchas polyvinylpyllolidone; and amino acids, monosaccharides,disaccharides, and other carbohydrates including glucose, mannose, ordextrins; chelating agents; and ionic and non-ionic surfactants (e.g.,polysorbate); salt-forming counter-ions such as sodium; metal complexes(e. g. Zn-protein complexes); and/or non-ionic surfactants.

The compositions can be administered in a “therapeutically effectivedose.” Single or multiple administrations of the compositions may beadministered depending on the dosage and frequency as required andtolerated by the subject. A “patient” or “subject” for the purposes ofthe present invention includes both humans and other animals,particularly mammals. Thus the methods are applicable to both humantherapy and veterinary applications. In the preferred embodiment thepatient is a mammal, preferably a primate, and in the most preferredembodiment the patient is human. Other known therapies can be used incombination with the methods of the invention.

Formulations suitable for oral administration can consist of (a) liquidsolutions, such as an effective amount of the packaged nucleic acidsuspended in diluents, such as water, saline or PEG 400; (b) capsules,sachets or tablets, each containing a predetermined amount of the activeingredient, as liquids, solids, granules or gelatin; (c) suspensions inan appropriate liquid; and (d) suitable emulsions. Tablet forms caninclude one or more of lactose, sucrose, mannitol, sorbitol, calciumphosphates, corn starch, potato starch, microcrystalline cellulose,gelatin, colloidal silicon dioxide, talc, magnesium stearate, stearicacid, and other excipients, colorants, fillers, binders, diluents,buffering agents, moistening agents, preservatives, flavoring agents,dyes, disintegrating agents, and pharmaceutically compatible carriers.Lozenge forms can comprise the active ingredient in a flavor, e.g.,sucrose, as well as pastilles comprising the active ingredient in aninert base, such as gelatin and glycerin or sucrose and acaciaemulsions, gels, and the like containing, in addition to the activeingredient, carriers known in the art.

The compositions of the present invention may be sterilized byconventional, well-known sterilization techniques or may be producedunder sterile conditions. Aqueous solutions can be packaged for use orfiltered under aseptic conditions and lyophilized, the lyophilizedpreparation being combined with a sterile aqueous solution prior toadministration. The compositions can contain pharmaceutically orphysiologically acceptable auxiliary substances as required toapproximate physiological conditions, such as pH adjusting and bufferingagents, tonicity adjusting agents, wetting agents, and the like, e.g.,sodium acetate, sodium lactate, sodium chloride, potassium chloride,calcium chloride, sorbitan monolaurate, and triethanolamine oleate.

The compound of choice, alone or in combination with other suitablecomponents, can be made into aerosol formulations (i.e., they can be“nebulized”) to be administered via inhalation. Aerosol formulations canbe placed into pressurized acceptable propellants, such asdichlorodifluoromethane, propane, nitrogen, and the like.

Suitable formulations for rectal administration include, for example,suppositories, which consist of the packaged nucleic acid with asuppository base. Suitable suppository bases include natural orsynthetic triglycerides or paraffin hydrocarbons. In addition, it isalso possible to use gelatin rectal capsules which consist of acombination of the compound of choice with a base, including, forexample, liquid triglycerides, polyethylene glycols, and paraffinhydrocarbons.

Formulations suitable for parenteral administration, such as, forexample, by intravenous, intramuscular, intraorgan, intratumoral,intradermal, intraperitoneal, and subcutaneous routes, include aqueousand non-aqueous, isotonic sterile injection solutions, which can containantioxidants, buffers, bacteriostats, and solutes that render theformulation isotonic with the blood of the intended recipient, andaqueous and non-aqueous sterile suspensions that can include suspendingagents, solubilizers, thickening agents, stabilizers, and preservatives.In the practice of this invention, compositions can be administered, forexample, by intravenous infusion, orally, topically, intraperitoneally,intravesically or intrathecally. Parenteral administration, oraladministration, and intravenous administration are the preferred methodsof administration. The formulations of compounds can be presented inunit-dose or multi-dose sealed containers, such as ampules and vials.

Injection solutions and suspensions can be prepared from sterilepowders, granules, and tablets of the kind previously described.

The pharmaceutical preparation is preferably in unit dosage form. Insuch form the preparation is subdivided into unit doses containingappropriate quantities of the active component. The unit dosage form canbe a packaged preparation, the package containing discrete quantities ofpreparation, such as packeted tablets, capsules, and powders in vials orampoules. Also, the unit dosage form can be a capsule, tablet, cachet,or lozenge itself, or it can be the appropriate number of any of thesein packaged form. The composition can, if desired, also contain othercompatible therapeutic agents.

Preferred pharmaceutical preparations deliver one or more agents.

In use, the active agent utilized in the methods of the invention areadministered at the initial dosage of about 0.001 mg/kg to about 1000mg/kg daily. A daily dose range of about 0.01 mg/kg to about 500 mg/kg,or about 0.1 mg/kg to about 200 mg/kg, or about 1 mg/kg to about 100mg/kg, or about 10 mg/kg to about 50 mg/kg, can be used. The dosages,however, may be varied depending upon the requirements of the patient,the severity of the condition being treated, the effect sought, and thecompound being employed. Determination of the proper dosage for aparticular situation is within the skill of the practitioner.

EXAMPLES

The following examples are offered to illustrate aspects of, but not tolimit, the claimed invention.

Example 1 Hepatocyte Transplantation (HT) Ameliorates Radiation-InducedLiver Damage (RILD) and Increases Survival after Partial HepaticResection and Irradiation (12)

Liver cancer is the sixth most common cancer worldwide in terms ofnumber of cases (626,00/yr) but because of very poor prognosis, thenumber of deaths is almost the same as its incidence (598,000/yr).Besides primary liver cancer, metastatic liver cancer, arising fromabdominal malignancies, remains a vexing and commonly encounteredproblem. Although, surgery is the only curative therapy, most patientswith liver tumors are unresectable and chemotherapy fails to curepatients. This is rather unfortunate because a significant proportion ofthese patients have limited hepatic metastases (oligometastases),without harboring tumor deposits in extrahepatic sites. Failure tocontrol the hepatic oligometastases results in eventual systemicprogression of the cancer. In many cancers, such as head and neck,esophagus, lung, cervix and rectal cancer, radiation therapy(RT)±chemotherapy improves local tumor control and survival of patients.But RT has been traditionally used in a palliative role because of thepotential for inducing potentially fatal RILD.

To simulate post-operative RT following resection of hepatic tumors, weexamined RILD in F344 rats after HIR and partial hepatectomy (PH).HIR/RT induced severe RILD as evidenced by increased mortality andhistopathological changes that included perivenous lobular collapse(FIG. 1A) with centrizonal steatosis (FIG. 1B), bile ductularproliferation and activation of liver stem cells, followed by periportalfibrosis (FIGS. 1D-E). Since RT inhibited hepatic regeneration, wehypothesized that transplantation of unirradiated hepatocytes, viaportal vein or intrasplenic injection, would result in preferentialproliferation of the donor cells in the partially resected andirradiated host liver. Transplanted hepatocytes would further providemetabolic support and ameliorate consequences and mortality associatedwith RILD. We tested this hypothesis in F344 rats where dipeptidylpeptidase-positive (DPPIV+ve) F344 hepatocytes were transplanted intocongeneic, DPPIV−ve F344 hosts after PH+HIR. We demonstrated that HTameliorated the histological changes of RILD (FIGS. 1C, F) and increasedsurvival of irradiated F344 rats (FIG. 2). By 12 weeks, donorhepatocytes constituted 76.9±3.9% of the host liver, in rats in thePH+HIR+HT group (FIGS. 3C,D). In contrast, among the rats that receivedPH without HIR, the donor cells accounted for only 12.7±1.8% of therecipient liver hepatocytes after 12 weeks (p=0.006, t-test) (FIG. 3).This is the first demonstration of amelioration of RILD by HT andindicates one can rescue liver function with HT in patients havingunresectable liver cancer after high dose chemo-RT.

Example 2 PH+HIR as a Preparative Regimen for Liver Repopulation byTransplanted Hepatocytes (Guha, C. et al., Hepatology, 36:354-362(2002))

Encouraged by our findings, we examined whether PH+HIR could be used asa preparative regimen of HT for amelioration of inherited metabolicliver diseases. Gunn rat is an animal model forbilirubin-uridinediphosphoglucuronate glucuronosyltransferase (UGT1A1)deficiency, which causes Crigler-Najjar syndrome type 1 in humans.UGT1A1 deficiency results in the lack of glucuronidation of bilirubin,resulting in the accumulation of unconjugated bilirubin in plasma andconsequent bilirubin encephalopathy. We transplanted congeneicUGT1A1-proficient, Wistar-RHA hepatocytes in jaundiced Gunn rats, 4 daysafter PH+HIR. Five months after HT, there was 60-80% repopulation of thehost liver by the engrafted UGT1A1+ve, transplanted hepatocytes (FIGS.4B-D). HPLC of bile collected 5 months after PH+HIR+HT showed completenormalization of the pigment profile, with excretion of conjugated bilepigments. There was complete normalization of serum bilirubin levels inthe transplanted Gunn rats, which received PH+HIR+HT. In this group(n=9), serum bilirubin concentrations declined from initial levels of10.4±2.3 mg/dl to completely normal levels (0.64±0.16 mg/dl) by 12 weeks(p=0.00012, t-test). In rats receiving either PH or HIR alone before HT,serum bilirubin concentrations declined by 25-30% in 28 weeks (FIG. 4E),indicating minimal repopulation. The complete normalization of serumbilirubin with PH+HIR has never been seen with current protocols of HTthat are available in the clinic for Crigler-Najjar patients. Theseresults indicate that HT in combination with a preparative regimen ofHIR can be a highly effective treatment for such patients.

Example 3 Noninvasive Substitutes to PH in the Preparative Regimen of HT

The success of PH+HIR as a preparative regimen for HT depends on HIRsuppressing the host hepatocellular proliferation and inducing mitoticcatastrophe in host cells, while PH providing the mitotic stimuli and aselective growth advantage for transplanted hepatocytes. Although PHprovides a very strong mitotic stimulus to the hepatocytes, it isinvasive and is not desirable in clinical protocols of liverrepopulation of transplanted hepatocytes for patients with metabolicdisorders. We, therefore, examined noninvasive alternatives to PH (Table2) (Takahashi, M. et al., Gene Ther, 10:304-313 (2003); Deb, N. et al.,Hepatology, 34 (4):153A., 34:153A (2001); Parashar, B. et al.,Hepatology, 32:206A (2000); Guha, C. et al., Am J Nephrol, 25:161-170(2005); Malhi, H. et al., Proc Natl Acad Sci USA, 99:13114-13119(2002)).

TABLE 2 HIR-BASED PREPARATIVE REGIMENS OF LIVER REPOPULATION(SUBSTITUTES TO PH) MECHANISM OF PREPARATIVE REGIMEN REPOPULATIONEFFICACY COMPENSATORY Fas-induced apoptosis in Extensive liverrepopulation REGENERATIVE STIMULI host cells  of transplanted 1. HIR +Anti-Fas or FasL PVBL-induced apoptosis  hepatocytes. Partial HIR  (Takahashi, M. et al., Gene Oxidative injury to host  results inselective   Ther, 10: 304-313 (2003)) HIR-induced injury to host repopulation in a single 2. HIR + Portal vein branch cells  lobe of theliver.    ligation (Deb, N. et al., Compensatory regenerative Potentialregimen for Cancer    Hepatology, 34 stimuli  patients.    (4): 153A.,34: 153A    (2001)) 3. HIR + Ischemia-reperfusion    injury (Malhi, H.et al.,    Proc Natl Acad Sci USA,    99: 13114-13119    (2002)) DIRECTHEPATIC  HIR-induced genotoxic Extensive repopulation. MITOGENS injuryto host  Partial HIR results in 4. HIR + Thyroid hormone (T3)  Hepaticmitogen provides  single lobe repopulation.  (Parashar, B. et al.,selective growth advantage Potential regimen for  Hepatology, 32: 206A(2000)) to transplanted cells  patients with metabolic 5. HIR +Adeno-Hepatocyte  disorders.    Growth Factor (HGF)    (Guha, C. et al.,Am J    Nephrol, 25: 161-170    (2005))

Our results demonstrate that HIR in combination with a variety ofmitotic stimuli (Table 2) can stimulate preferential proliferation oftransplanted hepatocytes in rat and mouse livers. These experimentsdemonstrated that HIR induces genotoxic injury to the host hepatocytes,resulting in cell cycle arrest, accelerated senescence and mitoticcatastrophe, in response to a mitotic stimulus, such as PH or HGF. Incontrast to the host hepatocytes, the nonirradiated transplantedhepatocytes preferentially proliferated in response to the same mitoticstimulus. The gradual loss of host hepatocytes over a period of 3-5months decreases the risk of sudden liver failure and providesregenerative stimuli to the transplanted cells over a long period oftime. This also gave the engrafted cells time to proliferate and providemetabolic support to the diseased liver.

PH, PVBL and Fas-based strategies can provide compensatory regenerativestimuli to donor cells, while the host cells are prevented from dividingby HIR. These methods can find use in patients with liver cancer wherethe tumor with adjacent host liver tissue can be resected or ablatedfollowed by HIR and transplantation of autologous hepatocytes afterpurging tumor cells (analogous with bone marrow rescue). The secondmethod can use direct hepatic mitogens, such as, T3 and HGF.Accordingly, these protocols can be applied in patients with inheritedor other liver diseases. Additionally, as shown in Table 2, a variety ofproliferative stimuli can be used in combination with HIR to promoteextensive liver repopulation by the transplanted cells.

Example 4 Focal Liver Irradiation for Selective Lobar Repopulation

Irradiation to a portion of the whole liver is well tolerated in cancerpatients. Doses higher than 50 Gy to parts of the liver can safely beoffered to patients in the clinic with modern techniques of 3-Dconformal RT or intensity-modulated RT. This is because clinical hepaticinjury induced by irradiation is a function of dose and the volume ofliver that is irradiated. Clinical trials have demonstrated that RILD orliver failure is not precipitated even when one-third of the liverreceives a RT dose of 70-80 Gy (Dawson, L. et al., Int J Radiat OncolBiol Phys, 53:810-821(2002); Dawson, L. et al., Semin Radiat Oncol,11:240-246 (2001)). We hypothesized that administration of focal liverirradiation would provide selective growth advantage of the engraftedhepatocytes, only in irradiated lobes. This would enable us torepopulate a single lobe of the liver or a portion of a single lobe bydelivering focal high dose HIR. To provide mitotic signals, acompensatory regenerative signal following right portal vein branchligation (PVBL) was used (see, Deb, N. et al., Hepatology, 34 (4):153A.,34:153A (2001)) (FIG. 5) and direct mitogens, Tri-iodo thyronine (T3)(FIG. 6), and HGF (FIG. 7). PVBL+partial HIR experiments were performedin DPPIV model, while adeno-HGF+partial HIR was performed in therosa/C57B1/6 model. As seen in FIGS. 5B-E, clusters of red DPPIV+vehepatocytes appeared by 3 weeks. There was gradual repopulation of theanterior irradiated lobes with near-total replacement of the lobe by 5months (FIG. 5E). In contrast, the posterior lobes that did not receiveHIR failed to be repopulated by the donor cells (FIG. 5F). The abilityof partial HIR to induce selective lobar repopulation was confirmed inthe rosa model of HT, following administration of adeno-HGF and HIR(FIG. 8). C57B1/6 mice received HIR (50 Gy) to the anterior liver lobesafter shielding the caudate and the right posterior lobe, followed by anintravenous injection of a recombinant adenoviral vector expressinghuman HGF (1×10¹¹ particles). Two days after HIR, they received atransplantation of 0.5-1.0 million congenic rosa hepatocytes, there wasselective repopulation of the irradiated anterior lobes (FIG. 8).Results show that adeno-HGF+HIR enabled near-total repopulation of thehost liver by beta-galactosidase-positive transgenic hepatocytes within4 months of HT (FIGS. 7-8). The ability to selectively repopulateportions of the liver is unique to HIR-based repopulation protocols. Itis contemplated for most metabolic liver diseases, functional correctionof a fraction of the liver mass (10-25%) would be sufficient forsignificant clinical benefit and cure. Thus, the use of focal HIR toselectively repopulate a portion of the liver can enhance the safetybecause the larger portion of the liver would not be subjected toirradiation.

Example 5 Ex Vivo UGT1A1 Gene Therapy for Gunn Rats Using PreparativeRegimens of Massive Liver Repopulation with Genetically ModifiedHepatocytes

Having described a safe and reproducible method of massive hepaticrepopulation, we wanted to evaluate whether the liver could berepopulated by hepatocytes that have been genetically modified ex vivo.We have used Gunn rat hepatocytes that had been conditionallyimmortalized by transduction with a thermolabile SV40 T antigen in ourlaboratory (Fox, I. et al., Hepatology, 21:837-846 (1995)). Thesehepatocytes proliferate at 33° C., but at physiological temperatures(37° C. to 39° C.), the T antigen is degraded, and the hepatocytes stopproliferating and exhibit liver-specific functions. The cells werefurther transduced using a retroviral vector expressing human UGT1A1 andseveral transduced colonies were cloned by serial dilution (Tada, K. etal., Liver Transpl Surg, 4:78-88 (1998)). We transplanted theseUGT1A1-transduced conditionally immortalized Gunn rat hepatocytes intoautologous Gunn rats after a preparative regimen of PH+HIR. FIG. 9A,shows the experimental design. Immunohistochemical staining usinganti-UGT1A1 antibodies demonstrate progressive repopulation of thegenetically engineered conditionally immortalized Gunn rat hepatocytesexpressing the human UGT1A1 transgene (FIG. 9B). By 16 weeks, there wasnear total replacement of the irradiated host liver. The physiologicalfunctioning of the transplanted cells was evident by the gradualdecrease in serum bilirubin with complete correction ofhyperbilirubinemia and jaundice by 12 weeks (FIG. 9C).

Example 6 Treatment of a Human with Chronic Liver Disease

Treatment of a human with metabolic or chronic liver failure as revealedby abnormal liver function tests is first treated with a dose of x-rayradiation 10 to 30 Gy to one or more lobes of the liver. The remainderof the exposed subject and liver is shielded from the radiation.Subsequently, 5×10¹⁰ to 5×10¹²ex vivo hepatocytes (freshly harvestedfrom a suitably matched human donor) per kg of body weight areadministered to the patient and the patient is started on a dailyregimen of recombinant human hepatocyte growth factor continuousinfusion over 1 to 3 days, repeated over several weeks and recombinantepidermal growth factor (1 mg/kg,) for two months and immunosuppressivetherapy. The irradiated portion of the liver is biopsied at 2, 4, and 8weeks and engrafted hepatocytes are identified by distinguishing cellsaccording to a difference in their genomic nucleic acid sequence. Liverfunction tests are performed weekly to assess liver function. Over theperiod of monitoring the number of engrafted cells as a percent of thebiopsied cells reaches 50% and the liver function tests return to morenormal values.

Example 7

In this report, we report on the differentiation of oval cells intoadult hepatocytes and bile ducts upon transplantation into liver thathas been treated with a preparative regimen of hepatic irradiation (HIR)and systemic injection with adenovirus expressing human hepatocytegrowth factor (Ad-HGF). We report that adult hepatic progenitor cellscan engraft, integrate and proliferate in irradiated rat livers thathave also received adeno-HGF.

Summary of Liver Stem Cell Transplantation Experiments

Although adult hepatic progenitor/stem cells (HPC) are normally not seenin the liver, they expand and regenerate an injured liver when primaryhepatocytes fail to proliferate. The role of HPC in the repair ofradiation-induced liver damage (RILD) is unknown. The question whetherHPCs would proliferate and compensate for parenchymal cell loss in arodent model of RILD, induced by partial hepatectomy (PH) and hepaticirradiation (HIR) was investigated in this example by examining whetherHPC proliferation is associated with liver regeneration after PH+HIR inF344 rats. Furthermore, the questions whether HPCs engraft andpreferentially proliferate and repopulate in an irradiated rat liverfollowing HIR and administration of a hepatic mitotic stimulus, such as,PH or administration of hepatocyte growth factor (HGF), wasinvestigated.

In these experiments, dipeptidyl peptidase IV (DPPIV)-deficient(DPPIV−ve) F344 rats received PH, followed by HIR (50Gy) to the anteriorliver lobes after exposing the liver by laparotomy and shielding theposterior liver lobes and other abdominal organs. Separate cohortsreceived HIR followed by an injection of a recombinant adenoviral vectorexpressing human HGF (Ad-HGF, 1×10¹¹ particles). One day after HIR,1×10⁷ freshly isolated, DPPIV-positive (DPPIV+ve) HPCs were transplantedinto the liver of the DPPIV−ve rats by intrasplenic injection. HPCs wereisolated from congeneic DPPIV+ve F344 rats that were previously treatedeither with D-galactosamine or with 2-acetylaminofluorence and PH toinduce hepatic injury. Since HPCs are smaller in size than adult primaryhepatocytes, HPCs were purified from the liver nonparenchymal cellfraction by discontinuous Nycodenz gradients or by using epithelial celladhesion molecule (EpCAM)-coated magnetic beads for positive selection.Animals were sacrificed at 2, 6 and 8 weeks after treatment.Proliferation of HPCs and liver repopulation were detected by OV-6immunohistochemistry and DPPIV histochemical staining.

With respect to activation and proliferation of oval cells inPH+HIR-treated animals. H&E staining of frozen liver sections revealedthat the OV-6+ve HPC cells were activated and proliferated between 2-6weeks after PH+HIR, indicating that HPC population participates in liverregeneration following HIR. Typically, oval cells appeared as smallsize, with an oval nucleus and scanty cytoplasm and were predominantlypresent at the interface between the portal tracts and the hepaticparenchyma. They formed tubular structures with poorly defined lumen andno basement membrane and were Immunoreactive for CK19, 0V6 and EpCAM.The distinct morphology and markers of oval cells were similar to thosedescribed in humans and rodents.

Hepatic oval cells were found to differentiate into hepatocytes and bileducts in irradiated liver. To determine the repopulation potential ofliver stem cells/HPC/oval cells in vivo, we isolated the ovalcell-enriched non-parenchymal cells from rat livers treated with D-galand 2-AAF, using the method of discontinuous Nycodenz density gradient.The non-parenchymal cells at the interface of 13% and 17% Nycodenzlayers were collected. The number of oval cells was estimated byhistochemical staining for GGT and immunostaining for CK19 and 15-20% ofGGT+/CK19+ oval cells was found at the fraction. To determine therepopulation capacity of the oval cells in vivo, 1×10⁷ of freshlyisolated oval enriched non-parenchymal cells were transplanted into theliver of the DPPIV deficient Fisher rats through intrasplenic injection.The transplanted DPPIV competent oval cells in the DPPIV deficient hostliver can be easily traced by histochemical staining or immunostainingfor DPPIV. The recipients were treated with HIR and Ad-HGF prior to celltransplantation. Six weeks after transplantation, the differentiationand repopulation of transplanted oval cells in the recipient liver wasevaluated. A significant part of recipient liver, around 40%, wasreplaced by transplanted oval cells (FIGS. 10 and 11). The regeneratedhepatocyte nodules showed typical linear bile canalicular stainingpattern for DPPIV. Around the regenerated hepatocyte nodules, DPPIVpositive duct structures were also observed (FIG. 10). CK19 stainingco-localized with the diffusely stained DPPIV ducts. These datademonstrated that transplanted oval cells showed bipotentialcharacteristic by differentiating into hepatic and biliary lineages inthe irradiated recipient liver.

HGF was found to stimulate the proliferation and differentiation oftransplanted oval cells in vivo. To define the condition of oval cellproliferation and differentiation in vivo, isolated oval cells weretransplanted into the liver of normal DPPIV deficient rats and DPPIVdeficient rats pretreated with Ad-HGF, HIR and HIR/Ad-HGF, respectively.Six weeks after cell transplantation, the repopulation of the liver wasevaluated by histochemical staining for DPPIV activity. Compared tocontrols (Ad-HGF alone or HIR alone), livers of the rats subjected toHIR/Ad-HGF were significantly replaced by the DPPIV+ hepatocytes after 6weeks (p<0.01) (FIG. 11). However, transplantation of oval cells innormal rats, and rats subjected to HIR alone or Ad-HGF alone yields fewscattered small DPPIV+ hepatocyte clusters, which indicating norepopulation (FIG. 12).

EpCAM+ cells showed liver repopulation capacity in the irradiated hostliver. EpCAM+HPCs were isolated from the oval cell enrichednon-parenchyma fraction (13/17%) using magnetic beads positive selection(FIG. 13) and their repopulation potential was evaluated in DPPIVdeficient rats pretreated with HIR/Ad-HGF. EpCAM+ cells were alsodemonstrated GGT+/CK19+ by histochemical staining for GGT andimmunostaining. Eight weeks after transplantation, radiation damagedhost liver was significantly replaced by DPPIV positive hepatocytes(FIG. 14). There was near-total replacement of irradiated hepaticparenchyma by transplanted HPCs within 6 weeks after transplantation.EpCAM+ve HPC fraction exhibited a 40-60% repopulation of irradiatedliver lobes by 8 weeks. In contrast, there was engraftment but minimalrepopulation of HPCs in rat livers that received AdHGF alone (p<0.01) orin liver lobes that were shielded from HIR. H&E staining demonstrated anormal liver architecture in livers that received HPC transplantationafter HIR.

Cholangiocarcinoma stem cells can be derived from oval cells and grownin rat livers. Oval cells are bipotential and are postulated tooriginate both hepatocellular or bile duct cancer. Oval cells that werecultured in vitro were transplanted into rats that received partialhepatectomy. Mitotic stimuli from partial hepatectomy resulted in thedevelopment of cholangiocarcinoma or bile duct cancer (FIGS. 15 and 16).Thus these models can be used to grow cancer stem cells in rat liverstreated with HIR/PH.

Accordingly, amplification of adult HPC population in a rodent model ofRILD has now been demonstrated. Adult HPC transplantation, combined witha hepatic mitotic stimulus, can engraft and rapidly regenerate livertissues following high doses of HIR. EpCAM+ve HPCs had strong liverrepopulation capacity. Accordingly, EpCAM is contemplated as a cellsurface marker for HPCs which can be used to purify HPC population fromdonor livers. As HPCs exhibit bipotential differentiation towards bothhepatocytic and biliary lineages, transplantation of HPCs can provide asalvage therapy for RILD and for the treatment of end-stage liverdiseases.

The referenced patents, patent applications, and scientific literature,including accession numbers to GenBank database sequences, referred toherein are hereby incorporated by reference in their entirety. Anyconflict between any reference cited herein and the specific teachingsof this specification shall be resolved in favor of the latter.Likewise, any conflict between an art-understood definition of a word orphrase and a definition of the word or phrase as specifically taught inthis specification shall be resolved in favor of the latter.

1. A method of treating a mammalian subject with an organ having areduced function by grafting mammalian ex vivo cells which supplementthe function and by promoting proliferation of the engrafted cells atthe site of engraftment, the method comprising the steps of: (a)administering to the subject an effective amount of an agent thatconfers a growth disadvantage to at least a subset of endogenous cellsat the site of engraftment; (b) administering to the subject aneffective amount of a mitogenic stimulus for the ex vivo cells; and (c)administering the ex vivo cells to the subject, wherein the ex vivocells engraft at the site and proliferate to a greater extent than thesubset of endogenous cells, to repopulate at least a portion of theengraftment site with the ex vivo cells, wherein the repopulated ex vivocells supplement or provide the function.
 2. The method of claim 1,wherein the organ with the reduced function is the intestine, liver,lung, kidney, pancreas, eye, testes, ovary, brain, spinal cord, or skin.3. (canceled)
 4. (canceled)
 5. The method of claim 1, wherein the exvivo cells are selected from the group consisting of adult somaticcells, adult progenitor cells, adult stem cells, embryonic progenitorcells, fetal cells, and embryonic stem cells from the same species asthe subject or from a different mammalian species than the subject. 6.The method of claim 1, wherein the ex vivo cells are heterologous orautologous to the subject, are cultured, expanded or modified prior totheir administration to the subject, or are harvested and sorted from aheterogeneous cell population prior to their administration to thesubject.
 7. (canceled)
 8. (canceled)
 9. (canceled)
 10. The method ofclaim 1, wherein the agent that confers a growth disadvantage to atleast a subset of endogenous cells is radiation, x-ray, gamma ray, or isselected from the group consisting of cytotoxic chemicals, ultrasound,heat, biological agents, misfolded proteins, and proteins or nucleicacids that suppress cell division.
 11. (canceled)
 12. (canceled) 13.(canceled)
 14. (canceled)
 15. The method of claim 1, wherein theadministered ex vivo cells have been genetically modified or comprise aheterologous gene that increases their intrinsic proliferation capacityor survival.
 16. The method of claim 1, wherein the mitogenic stimuluscomprises biological agents, antibodies and peptide factors thatincrease the proliferation capacity of the donor cells or a procedurethat deliberately injures the engraftment site to enable or to promoteentry and integration of the engrafted ex vivo cells into the hostparenchyma and/or to provide a compensatory growth signal for the exvivo cells.
 17. (canceled)
 18. (canceled)
 19. (canceled)
 20. (canceled)21. The method of claim 1, wherein the ex vivo cells are heterologous tothe engraftment site.
 22. The method of claim 1, wherein the engraftmentsite is the organ having the reduced function, or the engraftment siteis different from the organ having the reduced function.
 23. (canceled)24. (canceled)
 25. The method of claim 1, wherein the ex vivo cellsexpress a heterologous nucleic acid for gene therapy.
 26. (canceled) 27.(canceled)
 28. (canceled)
 29. (canceled)
 30. The method of claim 1,wherein the ex vivo cell expresses a protein not expressed by the hosttissue at the engraftment site and the presence of the protein is usedto selectively detect the ex vivo cells as opposed to the host cells atthe engraftment site.
 31. (canceled)
 32. A method of obtaining anexpanded population of ex vivo cells, comprising the steps of: (a)administering to a non-human mammalian subject an effective amount of anagent that confers a growth disadvantage to at least a subset ofendogenous cells at a site of engraftment; (b) administering to thenon-human mammalian subject an effective amount of a mitogenic stimulusfor the ex vivo cells; and (c) administering the ex vivo cells to thesubject, wherein the ex vivo cells engraft at the site and proliferateto a greater extent than the subset of endogenous cells, therebyrepopulating at least a portion of the engraftment site with the ex vivocells, and (d) harvesting the repopulated cells from the engraftmentsite; thereby obtaining the expanded ex vivo cell population.
 33. Themethod of claim 32, wherein the ex vivo cells are human.
 34. The methodof claim 32, wherein the ex vivo cells are selected from the groupconsisting of adult somatic cells, adult progenitor cells, adult stemcells, embryonic progenitor cells, fetal cells, xenogenic cells, andembryonic stem cells.
 35. The method of claim 32, wherein the ex vivocells heterologous to the non-human subject.
 36. The method of claim 32,wherein the agent that confers a growth disadvantage to at least asubset of endogenous cells of the organ is radiation, x-ray, gamma ray,or is selected from the group consisting of cytotoxic chemicals,ultrasound, heat, biological agents, misfolded proteins, and proteins ornucleic acids that suppress cell division.
 37. (canceled)
 38. (canceled)39. (canceled)
 40. The method of claim 32, wherein the ex vivo cell isderived from brain, intestinal, or liver tissue.
 41. (canceled) 42.(canceled)
 43. (canceled)
 44. A method of obtaining an expandedpopulation of ex vivo cells, comprising the steps of: (a) administeringto an irradiated organ ex vivo or in culture an effective amount of amitogenic stimuli for the ex vivo cells; wherein the irradiation confersa growth disadvantage to at least a subset of endogenous cells at a sitewhere the ex vivo cells engraft; and (b) administering the ex vivo cellsto the irradiated organ, wherein the ex vivo cells engraft at the siteand proliferate to a greater extent than the subset of endogenous cells,thereby repopulating at least a portion of the engraftment site with theex vivo cells, and (c) harvesting the repopulated cells from theengraftment site; thereby obtaining the expanded ex vivo cellpopulation. 45-52. (canceled)